Methods of Using Interleukin-2 Agonists

JP2024502708A5Active Publication Date: 2024-12-05VISTERRA INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534174
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2021-12-03
Publication Date
2024-12-05
Estimated Expiration
2041-12-03

AI Technical Summary

Technical Problem

There is an unmet need for novel interleukin-2 (IL-2) agents that are safe and effective for treating a variety of diseases and conditions, as current IL-2 therapies are limited by severe toxicities and are only effective for a small proportion of eligible patients.

Method used

Development of IL-2 agents with specific amino acid changes that stabilize the protein, reduce its affinity for CD122 and CD25, and selectively enhance regulatory T cell (Treg) activity through the IL-2 pathway, including IL-2 variants, fusion proteins, and conjugates, which can be used alone or in combination with other agents to treat autoimmune diseases and transplant rejection.

Benefits of technology

The modified IL-2 agents provide selective activation and expansion of regulatory T cells, reducing toxicity and enhancing immunosuppression, thereby treating autoimmune diseases and transplant rejection with improved safety and efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed are IL-2 agents, including IL-2 variants, and methods, compositions and uses thereof. The IL-2 agents described herein can be used to treat and / or prevent various disorders and conditions. Disclosed herein are IL-2 agents (e.g., IL-2 variants, IL-2 fusion proteins, IL-2 complexes, or IL-2 conjugates) that have one or more structural and / or functional properties described herein. Advantageously, some of the IL-2 agents described herein have one or more improved or desirable properties compared to IL-2 agents, including wild-type IL-2.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 121,726, filed December 4, 2020, and U.S. Provisional Application No. 63 / 283,822, filed November 29, 2021. The teachings of the foregoing applications are incorporated herein by reference in their entireties.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on December 1, 2021, is named P2029-7042WO_SL.txt and is 1,728,569 bytes in size. [Background technology]

[0003] Interleukin-2 (IL-2) is a cytokine that regulates the activity of the immune system. It is produced by white blood cells, such as T cells, natural killer (NK) cells, dendritic cells, and macrophages, in response to antigenic or mitogenic stimuli. IL-2 is important for T cell proliferation, B cell stimulation, and other activities related to immunity and tolerance. It is part of the body's adaptive immune response and distinguishes between foreign and host antigens. IL-2 mediates its effects by binding to the IL-2 receptor, which also activates downstream signaling events.

[0004] Human IL-2 is an FDA-approved drug for the treatment of diseases such as metastatic renal carcinoma and melanoma.The use of IL-2 in eligible patients is sometimes limited due to the serious toxicity associated with IL-2 treatment, and only a small proportion of eligible patients actually receive treatment.Toxicity associated with IL-2 treatment may include severe fever, nausea, vomiting, vascular leakage, and severe hypotension.However, despite these toxicities, IL-2 is usually effective in its approved indications.

[0005] There remains an unmet need for novel IL-2-based agents that are well characterized for the development of safe and effective therapeutics for patients with a variety of diseases and conditions amenable to treatment with IL-2. Summary of the Invention [Means for solving the problem]

[0006] The present disclosure provides IL-2 agents (e.g., IL-2 variants, IL-2 fusion proteins, IL-2 complexes, and IL-2 conjugates) that comprise, at least in part, one or more amino acid changes (e.g., substitutions) in IL-2 and that comprise one or more structural or functional properties disclosed herein. In one embodiment, nucleic acid molecules encoding the IL-2 agents, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), kits, containers, and methods of producing the IL-2 agents are also provided. The IL-2 agents disclosed herein can be used (alone or in combination with other agents or therapeutic modalities) to treat, prevent, and / or diagnose disorders, such as the disorders and conditions disclosed herein.

[0007] The present disclosure is based, at least in part, on the discovery that a combination of mutations in IL-2 that stabilize the protein, reduce its affinity for CD122 (e.g., the CD122 / CD132 heterodimer), and / or reduce or minimally affect its affinity for CD25 can be used to selectively enhance regulatory T cell (Treg) activity via the IL-2 pathway, thereby achieving beneficial therapeutic effects for treating disorders and conditions such as autoimmune diseases. IL-2 agents containing such mutations are suitable for treating conditions resulting from an aberrant immune response, e.g., autoimmune diseases.

[0008] Accordingly, in one aspect, the present disclosure provides a method of treating or preventing transplant rejection in a subject, the method comprising administering to the subject an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein.

[0009] In one embodiment, the subject has undergone, is undergoing, or will undergo a transplant. In one embodiment, the transplant rejection is graft-versus-host disease (GVHD).

[0010] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0011] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0012] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0013] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0014] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0015] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0016] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0017] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0018] In one embodiment, the method further comprises determining the activity of regulatory T cells (Tregs), for example, by an ex vivo suppression assay (eg, an ex vivo suppression assay described herein).

[0019] In one aspect, the present disclosure provides a method of treating transplant rejection in a subject, the method comprising administering to the subject an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein.

[0020] In one embodiment, the transplant rejection is graft-versus-host disease (GVHD).

[0021] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0022] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0023] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0024] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0025] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0026] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0027] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0028] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0029] In one embodiment, the method further comprises determining the activity of regulatory T cells (Tregs), for example, by an ex vivo suppression assay (eg, an ex vivo suppression assay described herein).

[0030] In one aspect, the disclosure provides a method of pretreating a subject prior to transplantation, the method comprising administering to the subject an effective amount of an IL-2 agonist, e.g., an IL-2 agonist described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein.

[0031] In one embodiment, pretreating a subject prior to transplantation includes increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample). In one embodiment, pretreating a subject prior to transplantation includes increasing the ratio of regulatory to non-regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-fold or more, compared to the ratio before administration of the IL-2 agent. In one embodiment, pretreating the subject prior to transplantation includes increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample) by, e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, compared to the ratio before administration of the IL-2 agent.

[0032] In one embodiment, the method further comprises administering an IL-2 fusion protein during and / or after the transplant.

[0033] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0034] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0035] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0036] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0037] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0038] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0039] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0040] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0041] In one embodiment, the method further comprises determining the activity of regulatory T cells (Tregs), for example, by an ex vivo suppression assay (eg, an ex vivo suppression assay described herein).

[0042] In one aspect, the disclosure provides a method of inducing and / or modulating, e.g., increasing, immunosuppression in a subject, comprising administering an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, wherein the subject has undergone, is undergoing, or will undergo a transplant.

[0043] In one embodiment, increasing immunosuppression in a subject comprises increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample). In one embodiment, increasing immunosuppression in a subject prior to transplant comprises increasing the ratio of regulatory to non-regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-fold or more, compared to the ratio before administration of the IL-2 agent. In one embodiment, increasing immunosuppression in a subject prior to transplant includes increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample) by, for example, about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, compared to the ratio before administration of the IL-2 agent.

[0044] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0045] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0046] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0047] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0048] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0049] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0050] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0051] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0052] In one embodiment, the method further comprises determining the activity of regulatory T cells (Tregs), for example, by an ex vivo suppression assay (eg, an ex vivo suppression assay described herein).

[0053] In one aspect, the disclosure provides a method of selectively increasing regulatory T cells in a subject, the method comprising administering to the subject an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, wherein the subject has undergone, is undergoing, or will undergo a transplant.

[0054] In one embodiment, regulatory T cells are increased, e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fold, compared to non-regulatory T cells. In one embodiment, regulatory T cells are increased, e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fold, compared to NK cells.

[0055] In one embodiment, regulatory T cells are increased relative to non-regulatory CD4+ cells, e.g., increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-fold or more, compared to non-regulatory CD4+ T cells. In one embodiment, regulatory T cells are increased relative to CD8+ cells, e.g., increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-fold or more, compared to CD8+ cells.

[0056] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0057] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0058] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0059] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0060] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0061] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0062] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0063] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0064] In one embodiment, the method further comprises determining the activity of regulatory T cells (Tregs), for example, by an ex vivo suppression assay (eg, an ex vivo suppression assay described herein).

[0065] In one aspect, the disclosure provides for the use of an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, in the manufacture of a medicament for treating or preventing a disorder in a subject, e.g., according to a method described herein.

[0066] In one aspect, the present disclosure provides an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, e.g., for use as a pharmaceutical, and a combination comprising a transplant.

[0067] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0068] In one embodiment, the combination further comprises one or more additional immunosuppressants selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0069] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0070] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0071] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0072] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0073] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0074] In one aspect, the present disclosure provides a combination, e.g., a combination described herein, e.g., a combination comprising an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, for use in treating or preventing transplant rejection in a subject.

[0075] In one embodiment, the transplant rejection is graft-versus-host disease (GVHD).

[0076] In one embodiment, the IL-2 agonist is administered to the subject before, during, and / or after transplantation.

[0077] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0078] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0079] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0080] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0081] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0082] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0083] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0084] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0085] In one aspect, the present disclosure provides a combination, e.g., a combination described herein, e.g., a combination comprising an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein or an IL-2 fusion protein described herein, and a transplant, for use in inducing and / or modulating, e.g., increasing, immunosuppression in a subject.

[0086] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0087] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0088] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0089] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0090] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0091] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0092] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0093] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0094] In one aspect, the present disclosure provides a combination, e.g., a combination described herein, e.g., a combination comprising an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein or an IL-2 fusion protein described herein, and a transplant, for use in selectively expanding regulatory T cells in a subject.

[0095] In one embodiment, the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant. In one embodiment, the transplant is a skin transplant.

[0096] In one embodiment, the method further comprises administering to the subject one or more additional immunosuppressive agents selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0097] In one embodiment, the IL-2 agent comprises an IL-2 variant described herein. In one embodiment, the IL-2 agent comprises an IL-2 fusion protein.

[0098] In one embodiment, the IL-2 agent comprises an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises (i) the amino acid substitutions H16L or H16N, and / or the amino acid substitution I92S, and (ii) the amino acid substitutions V69A, Q74P, and C125S corresponding to human IL-2 (SEQ ID NO: 1031). In one embodiment, the IL-2 variant further comprises the amino acid substitution T3A. In one embodiment, the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, an amino acid sequence at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, or 5 amino acids, or a functional fragment thereof.

[0099] In one embodiment, the IL-2 fusion protein further comprises an Fc region. In one embodiment, the Fc region comprises an Fc region of IgG1 allotype m3 containing an N297G substitution according to EU numbering. In one embodiment, the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence at least 95% identical thereto and differing therefrom by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or fewer amino acids, or a functional fragment thereof. In one embodiment, the Fc region is fused to the C-terminus of the IL-2 variant. In one embodiment, the fusion protein forms a dimer.

[0100] In one embodiment, the IL-2 fusion protein further comprises a linker. In one embodiment, the linker comprises (G4S)4 (SEQ ID NO: 48).

[0101] In one embodiment, the fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical thereto or that differs therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0102] In some embodiments, the subject is a human. In one embodiment, the subject is a non-human primate. In one embodiment, the subject is a mouse.

[0103] In one aspect, the present disclosure provides an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, for use in a method described herein in combination with a transplant (e.g., a transplant described herein).

[0104] In one aspect, the present disclosure provides a transplant (e.g., a transplant described herein) for use in a method described herein in combination with an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein.

[0105] In one aspect, the disclosure provides for the use of an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, in the manufacture of a medicament for treating or preventing a disorder described herein in combination with a transplant (e.g., a transplant described herein), e.g., according to a method described herein.

[0106] In one aspect, the disclosure provides for the use of a transplant (e.g., a transplant described herein) in the manufacture of a medicament for treating or preventing a disorder described herein in a subject, in combination with an IL-2 agent, e.g., an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, e.g., according to a method described herein.

[0107] In one aspect, the present disclosure provides a method of treating a disorder in a subject (e.g., a disorder described herein), comprising administering to the subject an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, wherein the subject is administered a different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein.

[0108] In one embodiment, administration of the different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein, is discontinued. In one embodiment, the different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein, does not comprise one or more of the mutations in an IL-2 agent described herein, e.g., an IL-2 variant described herein or an IL-2 fusion protein described herein. In one embodiment, the different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein, comprises aldesleukin (PROLEUKIN®).

[0109] In one aspect, the present disclosure provides an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, for use in a method of treating a disorder (e.g., a disorder described herein) in a subject, wherein the subject has been administered a different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein.

[0110] In one embodiment, administration of the different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein, is discontinued. In one embodiment, the different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein, does not comprise one or more of the mutations in an IL-2 agent described herein, e.g., an IL-2 variant described herein or an IL-2 fusion protein described herein. In one embodiment, the different IL-2 agent, e.g., a different IL-2 variant or a different IL-2 fusion protein, comprises aldesleukin (PROLEUKIN®).

[0111] The present disclosure also includes any of the following numbered embodiments: 1. A method of treating or preventing transplant rejection in a subject, comprising administering to the subject an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein.

[0112] 2. The method of embodiment 1, wherein the subject has undergone, is undergoing, or will undergo a transplant.

[0113] 3. A method of treating transplant rejection in a subject, comprising administering to the subject an IL-2 agent described herein, e.g., an IL-2 variant described herein or an IL-2 fusion protein described herein.

[0114] 4. The method of any one of embodiments 1 to 3, wherein the transplant rejection is graft-versus-host disease (GVHD).

[0115] 5. A method of pretreating a subject prior to transplantation, comprising administering to the subject an effective amount of an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein.

[0116] 6. The method of embodiment 5, wherein pretreating the subject prior to transplant comprises increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample).

[0117] 7. The method of embodiment 5 or 6, wherein pretreating the subject prior to transplant comprises increasing the ratio of regulatory to non-regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, compared to the ratio before administration of the IL-2 agent.

[0118] 8. The method of any one of embodiments 5 to 7, wherein pretreating the subject prior to transplant comprises increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, compared to the ratio before administration of the IL-2 agent.

[0119] 9. The method of any one of embodiments 5 to 8, wherein the method further comprises administering an IL-2 agonist during and / or after transplantation.

[0120] 10. A method of inducing and / or modulating, e.g., increasing, immunosuppression in a subject, comprising administering an IL-2 agent described herein, e.g., an IL-2 variant described herein, or an IL-2 fusion protein described herein, wherein the subject has undergone, is undergoing, or will undergo a transplant.

[0121] 11. The method of embodiment 10, wherein increasing immunosuppression in the subject comprises increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample).

[0122] 12. The method of embodiment 10 or 11, wherein increasing immunosuppression in the subject prior to transplant comprises increasing the ratio of regulatory to non-regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, compared to the ratio before administration of the IL-2 agent.

[0123] 13. The method of any one of embodiments 10 to 12, wherein increasing immunosuppression in the subject prior to transplantation comprises increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), e.g., by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, compared to the ratio before administration of the IL-2 agent.

[0124] 14. A method for selectively increasing regulatory T cells in a subject, comprising administering to the subject an IL-2 agent described herein, e.g., an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, wherein the subject has undergone, is undergoing, or will undergo a transplant.

[0125] 15. The method of embodiment 14, wherein regulatory T cells are increased, for example, by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fold compared to non-regulatory T cells.

[0126] 16. The method of embodiment 14 or 15, wherein regulatory T cells are increased, for example, by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times compared to NK cells.

[0127] 17. The method of any one of embodiments 14 to 16, wherein regulatory T cells are increased relative to CD4+ cells.

[0128] 18. The method of any one of embodiments 14 to 17, wherein regulatory T cells are increased relative to CD8+ cells.

[0129] 19. The method of any of the preceding embodiments, wherein the transplant is an organ transplant, a tissue (e.g., skin) transplant, or a cell transplant.

[0130] 20. The method of any of the preceding embodiments, further comprising administration of one or more additional immunosuppressants selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0131] 21. The method of any of the preceding embodiments, wherein the IL-2 agent comprises an IL-2 variant described herein.

[0132] 22. The method of any one of embodiments 1 to 18, wherein the IL-2 agent comprises an IL-2 fusion protein described herein.

[0133] 23. The method of any of the preceding embodiments, wherein the subject is a human or non-human primate.

[0134] 24. The method of any one of embodiments 1 to 22, wherein the subject is a mouse.

[0135] 25. The method of any of the preceding embodiments, further comprising determining the activity of regulatory T cells, e.g., by an ex vivo suppression assay (e.g., an ex vivo suppression assay described herein).

[0136] 26. An IL-2 agent described herein, for example, an IL-2 variant described herein, an IL-2 fusion protein described herein, an IL-2 complex described herein, or an IL-2 conjugate described herein, and a combination comprising a transplant.

[0137] 27. The combination of embodiment 26, wherein the IL-2 agent comprises an IL-2 variant as described herein.

[0138] 28. The combination according to embodiment 26, wherein the IL-2 agent comprises an IL-2 fusion protein as described herein.

[0139] 29. The combination according to any one of embodiments 26 to 28, further comprising one or more additional immunosuppressants selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0140] 30. The combination according to any one of embodiments 26 to 29, wherein the transplant is an organ transplant, a tissue transplant, or a cell transplant.

[0141] 31. A combination according to any one of embodiments 26 to 30 for use in preventing transplant rejection in a subject.

[0142] 32. The combination for use according to embodiment 31, wherein the transplant rejection is graft-versus-host disease (GVHD).

[0143] 33. The combination for use according to embodiment 31 or 32, wherein the IL-2 agent is administered to the subject before, during and / or after transplantation.

[0144] 34. A combination according to any one of embodiments 26 to 30 for use in inducing and / or modulating, e.g. increasing, immunosuppression in a subject.

[0145] 35. A combination according to any one of embodiments 26 to 30 for use in selectively increasing regulatory T cells in a subject.

[0146] 36. The combination according to any one of embodiments 31 to 35, wherein the subject is a human or non-human primate.

[0147] 37. The combination according to any one of embodiments 31 to 35, wherein the subject is a mouse.

[0148] The present disclosure also includes any of the following numbered embodiments: 1. An IL-2 agonist for use in a method of treating or preventing transplant rejection in a subject, comprising: The IL-2 agent comprises or consists of an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises a mutation set forth in Table 9, and optionally the IL-2 variant comprises: Corresponding to human IL-2 (SEQ ID NO: 1031) (i) the amino acid substitution H16L or H16N, and / or the amino acid substitution I92S, and (ii) amino acid substitutions V69A, Q74P and C125S IL-2 agonist, comprising:

[0149] 2. The IL-2 agent for use according to embodiment 1, wherein the subject has undergone, is undergoing, or is going to undergo a transplant.

[0150] 3. An IL-2 agonist for use in a method of treating transplant rejection in a subject, comprising: the subject has had, is undergoing, or will undergo a transplant; The IL-2 agent comprises or consists of an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises a mutation set forth in Table 9, and optionally the IL-2 variant comprises: Corresponding to human IL-2 (SEQ ID NO: 1031) (i) the amino acid substitution H16L or H16N, and / or the amino acid substitution I92S, and (ii) amino acid substitutions V69A, Q74P and C125S IL-2 agonist, comprising:

[0151] 4. The IL-2 agent for use according to any one of embodiments 1 to 3, wherein the transplant rejection is graft-versus-host disease (GVHD).

[0152] 5. An IL-2 agonist for use in a method of pretreating a subject prior to transplantation, comprising: the subject has had, is undergoing, or will undergo a transplant; The IL-2 agent comprises or consists of an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises a mutation set forth in Table 9, and optionally the IL-2 variant comprises: Corresponding to human IL-2 (SEQ ID NO: 1031) (i) the amino acid substitution H16L or H16N, and / or the amino acid substitution I92S, and (ii) amino acid substitutions V69A, Q74P and C125S IL-2 agonist, comprising:

[0153] 6. The IL-2 agent for use according to embodiment 5, wherein pre-treating the subject prior to transplant comprises increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample).

[0154] 7. The IL-2 agent for use of embodiment 5 or 6, wherein pretreating the subject prior to transplant comprises increasing the ratio of regulatory to non-regulatory T cells in the subject or a sample from the subject (e.g., a peripheral blood sample), optionally such that the ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more.

[0155] 8. The IL-2 agent for use of any one of embodiments 5 to 7, wherein pretreating the subject prior to transplant comprises increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), optionally wherein the ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more.

[0156] 9. The IL-2 agent for use according to any one of embodiments 5 to 8, wherein the method further comprises administering the IL-2 agent during and / or after transplantation.

[0157] 10. An IL-2 agonist for use in a method of inducing and / or modulating (e.g., increasing) immunosuppression in a subject, comprising: the subject has had, is undergoing, or will undergo a transplant; The IL-2 agent comprises or consists of an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises a mutation set forth in Table 9, and optionally the IL-2 variant comprises: Corresponding to human IL-2 (SEQ ID NO: 1031) (i) the amino acid substitution H16L or H16N, and / or the amino acid substitution I92S, and (ii) amino acid substitutions V69A, Q74P and C125S IL-2 agonist, comprising:

[0158] 11. The IL-2 agent for use according to embodiment 10, wherein increasing immunosuppression in the subject comprises increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample).

[0159] 12. The IL-2 agent for use of embodiment 10 or 11, wherein increasing immunosuppression in the subject prior to transplantation comprises increasing the ratio of regulatory to non-regulatory T cells in the subject or a sample from the subject (e.g., a peripheral blood sample), optionally wherein the ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-fold or more, e.g., compared to the ratio before administration of the IL-2 agent.

[0160] 13. The IL-2 agent for use according to any one of embodiments 10 to 12, wherein increasing immunosuppression in the subject prior to transplantation comprises increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), optionally wherein the ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more, e.g., compared to the ratio before administration of the IL-2 agent.

[0161] 14. An IL-2 agonist for use in a method for selectively increasing regulatory T cells in a subject, comprising: the subject has had, is undergoing, or will undergo a transplant; The IL-2 agent comprises or consists of an IL-2 variant or an IL-2 fusion protein comprising an IL-2 variant, wherein the IL-2 variant comprises a mutation set forth in Table 9, and optionally the IL-2 variant comprises: Corresponding to human IL-2 (SEQ ID NO: 1031) (i) the amino acid substitution H16L or H16N, and / or the amino acid substitution I92S, and (ii) amino acid substitutions V69A, Q74P and C125S IL-2 agonist, comprising:

[0162] 15. The IL-2 agent for use according to embodiment 14, wherein regulatory T cells are increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fold compared to non-regulatory T cells.

[0163] 16. The IL-2 agent for use according to embodiment 14 or 15, wherein regulatory T cells are increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fold compared to NK cells.

[0164] 17. The IL-2 agent for use according to any one of embodiments 14 to 16, wherein regulatory T cells are increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times compared to CD4+ cells.

[0165] 18. The IL-2 agent for use according to any one of embodiments 14 to 17, wherein regulatory T cells are increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times compared to CD8+ cells.

[0166] 19. IL-2 agonists for use as medicines in conjunction with transplantation.

[0167] 20. An IL-2 agent for use according to embodiment 19 in preventing transplant rejection in a subject.

[0168] 21. The IL-2 agent for use according to embodiment 20, wherein the transplant rejection is graft-versus-host disease (GVHD).

[0169] 22. An IL-2 agent for use according to embodiment 19 in inducing and / or modulating (e.g., increasing) immunosuppression in a subject.

[0170] 23. An IL-2 agent for use according to embodiment 19 in selectively increasing regulatory T cells in a subject.

[0171] 24. An IL-2 agent for use according to any one of embodiments 20 to 23, wherein the IL-2 agent is administered to the subject before, during and / or after transplantation.

[0172] 25. The IL-2 agent for use according to any one of embodiments 1 to 24, wherein the transplant is an organ transplant, a tissue transplant, or a cell transplant.

[0173] 26. The IL-2 agent for use according to any one of embodiments 1 to 25, wherein the transplant is a skin transplant.

[0174] 27. The IL-2 agent for use according to any one of embodiments 1 to 20, further comprising administration of one or more additional immunosuppressants selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

[0175] 28. The IL-2 agent for use according to any one of embodiments 1 to 27, wherein the IL-2 agent is an IL-2 variant.

[0176] 29. The IL-2 agent for use according to any one of embodiments 1 to 27, wherein the IL-2 agent is an IL-2 fusion protein.

[0177] 30. The IL-2 agent for use according to any one of embodiments 1 to 29, wherein the IL-2 variant further comprises the amino acid substitution T3A.

[0178] 31. The IL-2 agent for use according to any one of embodiments 1 to 30, wherein the IL-2 variant comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001 or 1002, an amino acid sequence that is at least 95% identical to the sequence or differs from the sequence by no more than 1, 2, 3, 4 or 5 amino acids, or a functional fragment thereof.

[0179] 32. The IL-2 agent for use according to any one of embodiments 1 to 27 or 29 to 31, wherein the IL-2 fusion protein further comprises an Fc region.

[0180] 33. An IL-2 agent for use according to embodiment 32, wherein the Fc region comprises an Fc region of the IgG1 allotype m3 comprising an N297G substitution according to EU numbering.

[0181] 34. The IL-2 agent for use according to embodiment 32 or 33, wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 1003, or an amino acid sequence that is at least 95% identical to the sequence and differs from the sequence by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0182] 35. The IL-2 agent for use according to any one of embodiments 32 to 34, wherein the Fc region is fused to the C-terminus of the IL-2 variant.

[0183] 36. The IL-2 agent for use according to any one of embodiments 1 to 27 or 29 to 35, wherein the IL-2 fusion protein further comprises a linker.

[0184] 37. The IL-2 agent for use according to embodiment 36, wherein the linker comprises (G4S)4 (SEQ ID NO: 48).

[0185] 38. The IL-2 agent for use according to any one of embodiments 1 to 27 or 29 to 37, wherein the fusion protein comprises an amino acid sequence of any of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009, an amino acid sequence that is at least 95% identical to the sequence or that differs from the sequence by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, or a functional fragment thereof.

[0186] 39. The IL-2 agent for use according to any one of embodiments 1 to 27 or 29 to 38, wherein the fusion protein forms a dimer.

[0187] 40. The IL-2 agent for use according to any one of embodiments 1 to 39, wherein the subject is a human or non-human primate.

[0188] 41. The IL-2 agent for use according to any one of embodiments 1 to 39, wherein the subject is a mouse.

[0189] 42. The IL-2 agent for use according to any one of embodiments 1 to 41, further comprising measuring the activity of regulatory T cells, for example by an ex vivo suppression assay (e.g., the ex vivo suppression assay described in Example 13). [Brief explanation of the drawings]

[0190] [Figure 1] Figure 1A provides a schematic diagram showing the domain structure of an exemplary, non-limiting embodiment of an IL-2 agent provided herein. The IL-2 agent includes an IL-2 portion or variant (also referred to herein as a "mutein"), a peptide linker, an Fc-containing hinge sequence, and antibody CH2 and CH3 domains, as shown. Figure 1B provides a depiction of the amino acid sequence of human IL-2 (SEQ ID NO: 1030) and shows exemplary, non-limiting positions that, when mutated, affect IL-2 receptor binding and IL-2-mediated signaling activity in vitro and in vivo.

[0191] [Figure 2] Figure 2 provides a schematic diagram illustrating a cell-based method for generating a library of IL-2 variants using yeast surface display and selecting stable and active clones from those libraries. Mutations of IL-2 or IL-2 variants expressed by initial clones are generated by DNA synthesis or error-prone PCR and transformed into yeast cells. Yeast cells are stained with an anti-Myc antibody and a fluorescent secondary antibody to determine IL-2 expression (x-axis) and with recombinant CD25, an anti-6xHis antibody ("6xHis" disclosed as SEQ ID NO: 1028), and a fluorescent secondary antibody to measure bound CD25 (y-axis). In some versions of the experiment, an HA tag is used in addition to or instead of the Myc tag. Fluorescence-activated cell sorting is used to enrich for IL-2 variants that exhibit both high expression and high binding activity.

[0192] [Figure 3]Figure 3A provides a graph showing the results of a method for determining the affinity and binding capacity of IL-2 muteins displayed on the surface of yeast using IL-2 receptor titration. Yeast clones expressing the indicated IL-2 muteins were incubated with various concentrations of 6xHis-tagged CD25 extracellular domain ("6xHis" disclosed as SEQ ID NO: 1028). Bound CD25 was measured by staining with an anti-6xHis antibody ("6xHis" disclosed as SEQ ID NO: 1028) and a fluorescent secondary antibody. Several exemplary IL-2 muteins are shown. Curve fitting was used to determine binding affinity (KD) and maximum binding signal (data not shown). Figure 3B provides a graph showing the relative binding capacity (maximum binding signal normalized to IL-2 expression level) for selected IL-2 muteins.

[0193] [Figure 4-1] Figure 4A provides a graph illustrating the thermal denaturation (melting curves) of selected IL-2 agents (IL-2-Fc fusion proteins) as determined by SYPRO Orange fluorescence. The native IL-2-Fc fusion exhibits a maximum signal at low temperatures, indicating the presence of unfolded protein, while the V69A / Q74P mutein exhibits unfolding events as the temperature increases. Figure 4B provides an HPLC size-exclusion chromatogram showing that the majority of the native IL-2-Fc fusion elutes very early from the column (>670 kDa), indicating unfolded protein aggregation. In contrast, V69A / Q74P IL-2-Fc elutes as a single peak at the expected time for an 84 kDa protein. [Figure 4-2] Same as above.

[0194] [Figure 5]Figures 5A-5B provide scatter plots showing the results of a yeast cell sorting procedure used to identify mutations affecting the interaction of CD122 and / or CD132 with the IL-2 receptor. Yeast expressing a library of IL-2 variants on their surface were stained with CD122 / CD132 Fc heterodimer at the indicated concentrations, and bound receptor was detected using a fluorescent anti-human Fc secondary antibody. Surface IL-2 expression was detected with an anti-Myc antibody and a fluorescent secondary antibody. Cells within the indicated gates (boxes) were sorted and collected, and the IL-2 muteins enriched in these populations were determined by a combination of Sanger sequencing and next-generation sequencing.

[0195] [Figure 6] Figure 6A provides a graph showing the results of a method to determine the saturation of yeast expressing the indicated IL-2 muteins on their surface after titration with CD122 / CD132 Fc heterodimer at the indicated concentrations. All muteins shown contain V69A / Q74P in addition to the indicated mutations. Bound CD122 / CD132 was labeled using an anti-human Fc fluorescent secondary and measured using an Accuri C6 flow cytometer. Saturation was calculated by fitting each curve to a four-parameter dose-response to estimate the maximum binding signal for each curve, then normalizing so that the estimated maximum was defined as 1. Figure 6B provides a graph showing the results of the same method as Figure 6A, except that selected muteins were incubated with 6xHis-tagged ("6xHis" disclosed as SEQ ID NO: 1028) recombinant CD25 extracellular domain, and bound CD25 was detected with an anti-6xHis antibody ("6xHis" disclosed as SEQ ID NO: 1028).

[0196] [Figure 7-1]Figure 7 provides a series of graphs showing the affinity of IL-2-Fc fusion proteins, including different IL-2 variants as indicated, for the extracellular domain of CD122 / CD132 Fc heterodimer and CD25, as measured with an Octet Biolayer Interferometer. The IL-2 variants contain V69A / Q74P plus the indicated mutations. The IL-2-Fc fusion proteins were immobilized on an anti-human Fc capture chip and then incubated with the indicated range of IL-2 receptor concentrations. Association and dissociation phase kinetics were used to estimate binding affinity. An excess of irrelevant antibody was used to prevent nonspecific binding or capture of the CD122 / CD132 Fc protein by the chip. [Figure 7-2] Same as above.

[0197] [Figure 8-1] Figure 8 provides a schematic diagram showing the gating strategy and corresponding flow cytometry data for identifying IL-2-sensitive cell populations from human PBMCs. Singlet lymphocytes were identified based on forward and side scatter. Populations were defined as regulatory T cells (CD4+CD25highFoxp3+), CD25high T helper cells (CD4+CD25highFoxp3-), and natural killer cells (CD3-CD56+). [Figure 8-2] Same as above.

[0198] [Figure 9-1]Figures 9A-9D provide graphs showing IL-2 signaling responses in IL-2-sensitive cell populations within human PBMCs (Figure 9A, Tregs; Figure 9B, CD25+(high) T helper cells; Figure 9C, NK cells; Figure 9D, CD8+ cytotoxic T cells) after treatment with IL-2-Fc fusions containing mutations that reduce affinity for the CD122 / CD132 dimer, as determined by the degree of STAT5 phosphorylation. Cells were treated for 30 minutes with IL-2-Fc fusion proteins containing the V69A / Q74 mutation plus the indicated mutations, or with the IL-2 N88D mutein (C-terminal N88D) fused to the C-terminus of a nonbinding antibody at the indicated concentrations. The inactive IL-2-Fc fusion protein contains several mutations that reduce its IL-2 signaling activity (F42A, Y45A, L72G, N88D, V69A, Q74P). After treatment, cells were fixed with formaldehyde, permeabilized with cold methanol, and stained for surface markers and the STAT5 transcription factor phosphorylated at Tyr694 (pSTAT5). Each population was identified based on the gating described in Figure 8. Selected muteins were also evaluated for signaling activity on CD8+ cytotoxic T cells. These cells were gated as in Figure 8, except that the CD8 surface marker was used instead of CD4. Median pSTAT5 levels (median fluorescence intensity (MFI)) are shown for each concentration of IL-2-Fc fusion protein tested in each cell population. Curve fitting was performed using GraphPad Prism v5.03 with a four-parameter fit for log(agonist) vs. response. [Figure 9-2] Same as above.

[0199] [Figure 10]Figures 10A-10C provide graphs showing IL-2 signaling responses in IL-2-sensitive cell populations within human PBMCs (Figure 10A, Tregs; Figure 10B, CD25+(high) T helper cells; Figure 10C, NK cells) following treatment with IL-2-Fc fusions containing mutations that reduce affinity for CD25. Human PBMCs were treated and analyzed as in Figure 9. Median values ​​(MFI) of pSTAT5 levels are shown for each treatment in each population. To highlight the effect on EC50, signaling within each mutein was normalized to 0-1 across the concentration range of IL-2-Fc treatments.

[0200] [Figure 11-1] Figures 11A-11C provide graphs showing IL-2 signaling responses in IL-2-sensitive cell populations within human PBMCs (Figure 11A, Tregs; Figure 11B, CD25+(high) T helper cells; Figure 11C, NK cells) after treatment with IL-2-Fc fusions containing paired mutations that reduce affinity for CD25 and CD122 / CD132. Human PBMCs were treated and analyzed as in Figure 9. IL-2-Fc fusion proteins containing various IL-2 muteins are separated into upper and lower panels for clarity, as indicated. Median values ​​(MFI) of pSTAT5 levels are shown for each treatment in each population. [Figure 11-2] Same as above. [Figure 11-3] Same as above.

[0201] [Figure 12]Figures 12A-12C provide graphs showing in vivo Treg expansion, measured as a percentage of total CD3+ T cells, in Tg32 mice treated with IL-2-Fc H16N (Figure 12A) or C-terminal N88D (Figure 12B). Homozygous Tg32 mice were administered the indicated amounts of each IL-2Fc fusion protein (dose levels were approximately equimolar) via tail vein injection. At the indicated time points, lymphocyte populations were profiled, and Tregs were defined as CD45+CD3+CD4+CD25highCD127- cells. Data in Figures 12A and 12B are the average of three mice per treatment group. Figure 12C shows data from individual mice at the highest dose of each IL-2-Fc fusion protein tested.

[0202] [Figure 13-1] Figures 13A-13C provide graphs showing the change in levels of CD4+ T helper cells, measured as a percentage of total CD3+ T cells, in Tg32 mice treated with IL-2-Fc H16N (Figure 13A) or C-terminal N88D (Figure 13B). Mice were dosed as in Figure 12. CD4+ T helper cells were defined as CD45+CD3+CD4+ cells that were not CD25highCD127-. Data in Figures 13A and 13B are the average of three mice per treatment group. Figure 13C shows data from individual mice at the highest dose of each IL-2-Fc fusion protein tested. [Figure 13-2] Same as above.

[0203] [Figure 14-1]Figures 14A-14C provide graphs showing the change in levels of CD8+ cytotoxic T cells, measured as a percentage of total CD3+ T cells, in Tg32 mice treated with IL-2-Fc H16N (Figure 14A) or C-terminal N88D (Figure 14B). Mice were dosed as in Figure 12. Cytotoxic T cells were defined as CD45+CD3+CD8+ cells. Data in Figures 14A and 14B are the average of three mice per treatment group. Figure 14C shows data from individual mice at the highest dose of each IL-2-Fc fusion protein tested. [Figure 14-2] Same as above.

[0204] [Figure 15-1] Figures 15A-15C provide graphs showing changes in NK cell levels, measured as a percentage of total CD45+ lymphocytes, in Tg32 mice treated with IL-2-Fc H16N (Figure 15A) or C-terminal N88D (Figure 15B). Mice were dosed as in Figure 12. NK cells were defined as CD45+CD3-CD56+ cells. Data in Figures 15A and 15B are the average of three mice per treatment group. In each case, the percentage of NK cells has been normalized within each mouse so that the pre-treatment value is 1. Figure 15C shows data from individual mice at the highest dose of each IL-2-Fc fusion protein tested. [Figure 15-2] Same as above.

[0205] [Figure 16-1] Figures 16A-16B provide graphs showing the binding kinetics of the CD122 / CD132 Fc heterodimer or the CD25 extracellular domain over a range of concentrations to IL-2-Fc fusion proteins containing only the V69A / Q74P mutation (wild-type, Figure 16A) or inactivating mutations (42A, Y45A, L72G, N88D, V69A, Q74P; inactive, Figure 16B) immobilized on an anti-human Fc Octet chip. The binding kinetics were used to estimate the KD of each interaction. [Figure 16-2] Same as above.

[0206] [Figure 17-1] Figures 17A-17D provide graphs illustrating the clearance kinetics of IL-2Fc fusion proteins in mice. Plasma was collected from mice treated as in Figure 12 with various doses of IL-2-Fc fusion proteins containing the V69A / Q74P / H16N mutations or the C-terminal N88D (Figures 17A-17B) or IL-2-Fc fusion proteins containing inactivating mutations (42A, Y45A, L72G, N88D, V69A, Q74P; inactive; Figures 17C-17D), as indicated. The amount of IL-2-Fc or C-terminal N88D present at each time point was measured using an ELISA assay with an anti-IL-2 capture antibody (R&D Systems, AF-202) and an anti-human Fc secondary antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch 109-035-008). 100% of the starting material was defined as the amount detectable in plasma 1 hour after injection. Note that the x-axis is categorical and not scaled with time. [Figure 17-2] Same as above.

[0207] [Figure 18-1]Figures 18A-18D show in vivo immune cell expansion in humanized mice following administration of exemplary IL-2Fc fusion proteins. Figure 18A shows a schematic diagram of the experimental design, illustrating various time points at which blood was collected from humanized mice administered IL-2Fc fusion polypeptides and control polypeptides. Flow cytometry was used to measure various lymphocyte populations at each indicated time point. Figure 18B shows the expansion rate of regulatory T cells on the Y-axis and the corresponding dose (low or high) on the X-axis for each IL-2Fc fusion polypeptide. Figure 18C shows the expansion rate of T helper cells on the Y-axis and the corresponding dose (low or high) on the X-axis for each IL-2Fc fusion polypeptide. Figure 18D shows the expansion rate of NK cells on the Y-axis and the corresponding dose (low or high) on the X-axis for each IL-2Fc fusion polypeptide. As shown from left to right on the X-axis of Figures 18B-18D, the IL-2Fc fusion polypeptides examined were: a control monoclonal antibody (motavizumab), inactive IL-2, an IL-2 mutein containing the N88D mutation, wild-type IL-2, an IL-2 mutein containing the mutations H16N / V69A / Q74P / C125S (SEQ ID NO: 1007), and an IL-2 mutein containing the mutations H16L / V69A / Q74P / C125S (SEQ ID NO: 1008). [Figure 18-2] Same as above. [Figure 18-3] Same as above. [Figure 18-4] Same as above.

[0208] [Figure 19] Figures 19A-19B show the residual amounts of exemplary IL-2 fusion proteins in Tg32 mice. Figure 19A shows the concentration of IL-2 fusion proteins with the indicated mutation combinations in the blood of mice on the Y-axis, with the number of days sampled after administration on the X-axis. Figure 19B shows a comparison of the half-life of IL-2 fusion proteins with and without additional mutations in the Fc region, with the indicated mutation combinations in the IL-2 moiety. The concentration of the indicated IL-2 fusion protein in the blood is shown on the Y-axis, and the number of days after administration is shown on the X-axis.

[0209] [Figure 20] Figure 20 shows the pharmacokinetic profile of an exemplary IL-2-Fc fusion protein (IL2-118 fused to IgG1 Fc N297G allotype m3) containing the mutations H16L / V69A / Q74P / C125S (SEQ ID NO: 1008) in cynomolgus monkeys. Four monkeys (numbers 3501, 3502, 3503, and 3504) were injected with 100 μg / kg of IL-2-Fc fusion protein four times per week, and serum levels of IL-2-Fc fusion protein were measured over time.

[0210] [Figure 21] Figures 21A-21B show the effect of an exemplary IL-2-Fc fusion protein (containing mutations H16L / V69A / Q74P / C125S (SEQ ID NO: 1008) (IL2-118 fused to IgG1 Fc N297G allotype m3)) on regulatory T cell expansion and proliferation in cynomolgus monkeys. Figure 21A shows regulatory T cell expansion, expressed as fold change over baseline (baseline = pre-dose), over time after four weekly injections of 100 μg / kg of IL-2-Fc fusion protein. Figure 21B shows the percentage of Ki67+ regulatory T cells normalized to total regulatory T cells (an indicator of proliferating regulatory T cells) over time after four weekly injections of 100 μg / kg of IL-2-Fc fusion protein.

[0211] [Figure 22-1]Figures 22A-22D show the effect of an exemplary IL-2-Fc fusion protein (containing mutations H16L / V69A / Q74P / C125S (SEQ ID NO: 1008) (IL2-118 fused to IgG1 Fc N297G allotype m3)) on circulating immune cells in cynomolgus monkeys after four weekly injections of 100 μg / kg of IL-2-Fc fusion protein. Figure 22A shows the effect of the IL-2-Fc fusion protein on the number of NK cells over time, Figure 22B shows the effect on cytotoxic T cells over time, Figure 22C shows the effect on T helper cells over time, and Figure 22D shows the effect on total T cells over time. Data are presented as fold change over baseline (baseline = pre-dose) for each cell type. [Figure 22-2] Same as above.

[0212] [Figure 23-1] Figures 23A-23C show the effect of an exemplary IL-2-Fc fusion protein described herein on disease progression in a mouse model of systemic lupus erythematosus with kidney pathology resembling lupus nephritis. Figure 23A shows the proteinuria scores measured weekly in mice after treatment with 40 μg / kg of an exemplary IL-2-Fc fusion protein or a PBS vehicle control administered every three days from 3 to 18 weeks of age. Proteinuria scores are shown on the Y-axis, and the age of the mice in weeks is shown on the X-axis. Figure 23B shows a series of graphs showing the proteinuria scores on the Y-axis in individual mice treated with a vehicle control or an exemplary IL-2-Fc fusion protein, as indicated on the X-axis. From left to right, the first panel shows the proteinuria scores at 11 weeks of age, the middle panel shows the scores at 12 weeks of age, and the last panel shows the scores at 13 weeks of age. FIG. 23C shows quantified glomerular pathology on the Y-axis in individual mice treated with vehicle control or exemplary IL-2-Fc fusion proteins at the end of the study (when mice reached 18 weeks of age), as shown on the X-axis. [Figure 23-2] Same as above.

[0213] [Figure 24-1]Figures 24A-H show the effect of an exemplary human IL-2 mutein (termed mIL-2) containing a human antibody Fc partial domain (IL-2-Fc) (mutation H16L / V69A / Q74P / C125S (SEQ ID NO: 1008) (IL2-118 fused to IgG1 Fc N297G allotype m3)) on skin graft viability and regulatory T cell numbers and function. Figure 24A represents Kaplan-Meier curves of percent skin allograft survival over days post-transplant in mice treated with mIL-2 or PBS control. Groups were compared using the log-rank test. Figure 24B represents the percentage of circulating regulatory T cells over days post-transplant in mice treated with mIL-2 or PBS control. Figure 24C represents the percentage of circulating NK cells over days post-transplant in mice treated with mIL2 or PBS control. Figure 24D shows the percentage of proliferating T cells (mean ± SD) versus the Treg:Tconv ratio in mice treated with mIL-2 or an inactive IL-2-Fc control (*p<0.05, **p<0.01 by two-way ANOVA with Tukey's post-hoc test). Data represent pools of two animals per group, and all data were performed in triplicate. Figure 24E shows the proliferation of blood and spleen Tregs after continuous infusion of mIL-2 or control IgG. Figure 24F shows the levels of functional markers after a single injection of mIL-2 or control IgG. Figure 24G shows the levels of blood Tregs and NK cells in male-to-female skin grafts in B6 mice treated with mIL-2 or control IgG. Figure 24H shows graft survival in male-to-female skin grafts in B6 mice treated with mIL-2 or control IgG. [Figure 24-2] Same as above. [Figure 24-3] Same as above. [Figure 24-4] Same as above. [Figure 24-5] Same as above. [Figure 24-6] Same as above.

[0214] [Figure 25-1]Figures 25A-25C show the dose-dependent effect of an exemplary IL-2-Fc fusion protein (IL2-118 fused to IgG1 Fc N297G allotype m3 containing mutation H16L / V69A / Q74P / C125S (SEQ ID NO: 1008)) (referred to as mIL-2) on circulating immune cells in non-human primates following a single subcutaneous injection of 100 μg / kg, 33 μg / kg, 14 μg / kg, or 4 μg / kg of IL-2-Fc fusion protein compared to a placebo control. Figure 25A shows the dose-dependent effect of the IL-2-Fc fusion protein on the fold change from baseline in regulatory T cells over time. Figure 25B shows the dose-dependent effect of the IL-2-Fc fusion protein on the percentage of proliferating regulatory T cells compared to total regulatory T cells over time. FIG. 25C shows the dose-dependent effect of IL-2-Fc fusion protein on the fold change from baseline in NK cells over time. [Figure 25-2] Same as above.

[0215] [Figure 26-1]Figures 26A-26D show the dose-dependent effect of an exemplary IL-2-Fc fusion protein (IL2-118 fused to IgG1 Fc N297G allotype m3) containing mutation H16L / V69A / Q74P / C125S (SEQ ID NO: 1008)) (referred to as mIL-2) on circulating immune cells in non-human primates after a single subcutaneous injection of 100 μg / kg, 33 μg / kg, 14 μg / kg, or 4 μg / kg of IL-2-Fc fusion protein compared to five daily injections of 37 μg / kg or 5 μg / kg of Proleukin control. Figure 26A shows the dose-dependent effect of IL-2-Fc fusion protein compared to Proleukin on the fold change from baseline in the Treg:Tcon ratio over time. Figure 26B shows the dose-dependent effect of IL-2-Fc fusion protein compared to Proleukin on the fold change from baseline in T helper cells over time. Figure 26C shows the dose-dependent effect of IL-2-Fc fusion protein compared to Proleukin on the fold change from baseline in T cytotoxic cells over time. Figure 26D shows the dose-dependent effect of IL-2-Fc fusion protein compared to Proleukin on the fold change from baseline in NK cells over time. [Figure 26-2] Same as above. [Figure 26-3] Same as above.

[0216] [Figure 27] Figure 27 shows the dose-dependent effect of an exemplary IL-2-Fc fusion protein (containing mutations H16L / V69A / Q74P / C125S (SEQ ID NO: 1008) (IL2-118 fused to IgG1 Fc N297G allotype m3)) (referred to as mIL-2) on the induction of T regulatory cells in non-human primates following a single subcutaneous injection of 100 μg / kg, 33 μg / kg, or 14 μg / kg of the IL-2-Fc fusion protein compared to five daily injections of a low-dose (5 μg / kg) Proleukin control over time.

[0217] [Figure 28]Figures 28A-28E show the dose-dependent effect of an exemplary IL-2-Fc fusion protein (IL2-118 fused to IgG1 Fc N297G allotype m3) containing mutation H16L / V69A / Q74P / C125S (SEQ ID NO: 1008)) (referred to as mIL-2) on the induction of T regulatory cells in non-human primates after a single subcutaneous injection of 100 μg / kg of IL-2-Fc fusion protein compared to five daily injections of a high-dose (37 μg / kg) Proleukin control over time. Figure 28A shows the effect of 100 μg / kg of IL-2-Fc fusion protein compared to a high-dose Proleukin control on the fold change from baseline in regulatory T cells over time. Figure 28B shows the effect of 100 μg / kg IL-2-Fc fusion protein compared to a high-dose Proleukin control on the ratio of Treg:Tcon over time. Figure 28C shows the effect of 100 μg / kg IL-2-Fc fusion protein compared to a high-dose Proleukin control on the fold change from baseline in T helper cells over time. Figure 28D shows the effect of 100 μg / kg IL-2-Fc fusion protein compared to a high-dose Proleukin control on the fold change from baseline in cytotoxic T cells over time. Figure 28E shows the effect of 100 μg / kg IL-2-Fc fusion protein compared to a high-dose Proleukin control on the fold change from baseline in NK cells over time.

[0218] [Figure 29-1]Figure 29A compares the pharmacokinetic profiles over time in non-human primates of an exemplary IL-2-Fc fusion protein (IL2-118 fused to IgG1 Fc N297G allotype m3 containing mutation H16L / V69A / Q74P / C125S (SEQ ID NO: 1008)) (referred to as mIL-2) compared to a wild-type IL-2 Fc control after a single injection at concentrations of 100 μg / kg, 33 μg / kg, 14 μg / kg, or 4 μg / kg. Figure 29B shows the pharmacokinetic profiles over time in non-human primates of the Proleukin control after five daily injections at concentrations of 37 μg / kg or 5 μg / kg. The dotted line in each figure is the lower limit of detection (LLOQ), approximately 3 ng / mL. [Figure 29-2] Same as above. DETAILED DESCRIPTION OF THE INVENTION

[0219] Detailed Description Disclosed herein are IL-2 agents (e.g., IL-2 variants, IL-2 fusion proteins, IL-2 complexes, or IL-2 conjugates) having one or more structural and / or functional properties described herein. Advantageously, some of the IL-2 agents described herein have one or more improved or desirable properties compared to IL-2 agents, including wild-type IL-2. Without wishing to be bound by theory, in one embodiment, the IL-2 agents described herein are believed to selectively enhance regulatory T cell (Treg) activity via the IL-2 pathway. Also provided are nucleic acid molecules encoding the IL-2 agents, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), kits, containers, and methods for producing the IL-2 agents. The IL-2 agents and pharmaceutical compositions disclosed herein can be used (alone or in combination with other agents or treatment modalities) to treat, prevent, and / or diagnose disorders and conditions, e.g., disorders and conditions associated with T cell activity, e.g., a disorder or condition described herein (e.g., an autoimmune disorder described herein).

[0220] Immune responses are typically controlled by the recognition of specific foreign or self-antigens, communication between innate and adaptive immune pathways, crosstalk between B cells and T cells, and other factors. Some autoimmune diseases can be characterized by widespread recognition of self-antigens. These diseases can be treated with therapies that broadly enhance the process that protects self-antigens from immune attack. Tregs are a type of T cell that recognizes self-antigens. In response to antigen stimulation, Tregs release immunosuppressive cytokines and directly inhibit other T cells through cell-to-cell contact. Impaired Treg activity can lead to a wide range of autoimmune disorders (e.g., too few or underactive cells). IL-2 is a cytokine that triggers the expansion and activation of many cell types, but Tregs are typically much more sensitive to IL-2 than other cell types. Administration of low doses of IL-2 has been shown to preferentially and sustainably expand Treg cells in vivo, accompanied by improvement in chronic graft-versus-host disease (GVHD) conditions in a significant proportion of patients (Koreth et al., N Engl J Med. 2011;365(22):2055-2066). In one embodiment, the IL-2 agents described herein provide long-lived immunomodulatory (e.g., immunosuppressant) agents for a number of disorders (e.g., autoimmune indications).

[0221] Long-term immunosuppression can place transplant patients at greater risk of infection, malignancy, and nephrotoxicity, and alternative approaches to immune system modulation are needed. Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 agents as described herein can provide immunomodulation and suppression while reducing or minimizing the effects on effector cells and expanding regulatory T cells in subjects who are or have received a transplant, e.g., an organ or tissue transplant.

[0222] The present disclosure is based, at least in part, on the discovery that IL-2 agents comprising human IL-2 polypeptides having specific combinations of amino acid substitutions described herein can have advantageous technical effects, such as increasing the stability of the IL-2 agent and / or providing selective activation of regulatory T cells. The IL-2 agents described herein typically require CD25 for efficient signaling through the IL-2 receptor, resulting in high selectivity for Tregs. IL-2 signaling promotes Treg suppressor function and promotes proliferation. Without wishing to be bound by theory, it is believed that Tregs activated by the IL-2 agents described herein can attenuate autoimmune activity through various mechanisms.

[0223] In one embodiment, the IL-2 agents described herein selectively bind to and activate regulatory T cells, while simultaneously activating other immune cell types (e.g., CD25 highIt has been found that the IL-2 agonist has a lack of effect on regulatory T cells (T cells and NK cells). Without wishing to be bound by theory, in one embodiment, the amino acid substitutions described herein are believed to promote the ability of the IL-2 agonist to maintain an active conformation and modulate the binding affinity of the IL-2 agonist to dimeric receptors comprising IL-2Rβ (CD122) and IL-2Rγ (CD132), and trimeric receptors comprising IL-2Rα (CD25) together with CD122 and CD132. In one embodiment, the IL-2 agonist described herein has optimal affinity to selectively bind and activate IL-2 signaling in regulatory T cells, resulting in the activation and expansion of regulatory T cells selectively both in vitro and in vivo. Without wishing to be bound by theory, in one embodiment, the binding of IL-2 to the IL-2 receptor is believed to be the primary clearance pathway for IL-2 in vivo. For example, IL-2 agents described herein with reduced affinity for dimeric and trimeric IL-2 receptors exhibit extended half-lives, demonstrating that reduced affinity for the IL-2 receptor reduces clearance of the IL-2 agent in vivo. IL-2 agents described herein, for example, those with amino acid substitutions that increase stability and decrease affinity for the IL-2 receptor, can selectively activate regulatory T cells and exhibit increased half-life in vivo. IL-2 agents described herein, for example, those with mutations that prevent CD25 binding, can have improved half-life in vivo. In one embodiment, the IL-2 agent does not promote, or does not substantially promote, the expansion, activation, survival, and / or proliferation of T effector cells and / or NK cells in vitro and / or in vivo. Without wishing to be bound by theory, in one embodiment, it is believed that the IL-2 agents described herein may have a larger therapeutic window than low-dose IL-2.

[0224] There are various technical effects associated with the presence of the particular set of mutations described herein, e.g., a set of mutations comprising an amino acid substitution at position H16 in combination with amino acid substitutions at positions V69, Q74, and C125 (e.g., H16L, V69A, Q74P, and C125S). Without wishing to be bound by theory, in one embodiment, an IL-2 agent (e.g., an IL-2 variant or IL-2 fusion protein) comprising H16L, V69A, Q74P, and C125S is believed to be significantly stable, e.g., due to the presence of the stabilizing V69A and Q74P mutations. For example, it has been unexpectedly discovered that the V69A and Q74P substitutions do not substantially increase (or essentially decrease) the binding affinity of the IL-2 agent for CD25, but rather stabilize the IL-2 agent in an active conformation sufficient for binding to CD25. Without wishing to be bound by theory, in one embodiment, IL-2 agents containing the aforementioned mutations are believed to have reduced binding affinity to CD122 and / or CD132, increasing the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) compared to other T cell types. Accordingly, IL-2 agents containing these mutations are typically stable and selectively activate regulatory T cells (Tregs). Without wishing to be bound by theory, in one embodiment, IL-2 agents containing the aforementioned mutations are believed to have reduced or diminished binding ability and / or binding affinity to CD25, thereby improving the longevity of the IL-2 agent. Without wishing to be bound by theory, in one embodiment, IL-2 agents containing these mutations are believed to not substantially promote the expansion, activation, survival, and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo. In one embodiment, an IL-2 agent comprising the H16L mutation has reduced binding affinity to CD122 and / or CD132 and / or increased potency and selectivity for Tregs over other T cell types compared to IL-2 agents comprising other H16 mutations.These properties make IL-2 agents containing the aforementioned mutations particularly suitable for the treatment of disorders and conditions resulting from an aberrant immune response, such as autoimmune diseases.

[0225] Thus, in one embodiment, an IL-2 agonist (e.g., an IL-2 variant or IL-2 fusion protein) comprising an amino acid substitution at position H16 in combination with amino acid substitutions at positions V69, Q74, and C125 (e.g., H16L, V69A, Q74P, and C125S) has, inter alia, one or more (e.g., two, three, four, five, six, seven, or all) of the following properties compared to a wild-type IL-2 or reference IL-2 agonist that does not comprise the amino acid substitution: (i) enhanced or increased stability in vitro or in vivo; (ii) reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 agonist for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased (e.g., moderately reduced or decreased) binding ability and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) regulatory T cells (e.g. Foxp3 + selective binding to T cells; (vii) selective activation of the IL-2 signaling pathway in regulatory T cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote the expansion, activity, survival and / or proliferation of Tregs.

[0226] definition As used herein, the articles "a" and "an" refer to one or to more than one (e.g., to at least one) of the grammatical object of the article.

[0227] The term "or" is used herein to mean, and is used interchangeably with, the term "and / or," unless context clearly dictates otherwise.

[0228] "About" and "approximately" generally refer to an acceptable degree of error for the quantity being measured, given the nature or precision of the measurement. Exemplary degrees of error are within 20 percent (%), typically within 10%, and more typically within 5% of a given value or range of values. When "about" or "approximately" precedes a series of numbers or ranges, it is understood that "about" or "approximately" may modify each number in the series or range. Similarly, when "at least," "greater than," "less than," "more than," or "within" precedes a series of numbers or ranges, it is understood that "at least," "greater than," "less than," "more than," or "within" may modify each number in the series or range. As used herein, a range includes both upper and lower limits.

[0229] The compositions and methods disclosed herein encompass polypeptides and nucleic acids having the designated sequences or sequences substantially identical or similar thereto, for example, sequences at least 85%, 90%, 95% or more identical to the designated sequences.

[0230] In the context of amino acid sequences, the term "substantially identical" is used herein to refer to a first amino acid sequence that contains a sufficient or minimum number of amino acid residues that are i) identical to or ii) conservative substitutions for aligned amino acid residues in a second amino acid sequence, such that the first and second amino acid sequences may have a common structural domain and / or a common functional activity. For example, an amino acid sequence containing a common structural domain that has at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a reference sequence, e.g., a sequence provided herein.

[0231] In the context of nucleotide sequences, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of identical nucleotides to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode polypeptides having a common functional activity, or encode a common structural polypeptide domain or common functional polypeptide activity. For example, a nucleotide sequence having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a reference sequence, e.g., a sequence provided herein.

[0232] The term "functional variant" refers to a polypeptide that has substantially the same amino acid sequence as a naturally occurring sequence, or is encoded by substantially the same nucleotide sequence, and that can possess one or more activities of the naturally occurring sequence.

[0233] Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

[0234] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison (for example, for optimal alignment, gaps can be introduced into one or both of the first and second amino acid or nucleic acid sequences, and non-homologous sequences can be ignored for comparison purposes). In a typical embodiment, the length of the reference sequence that is aligned for comparison purposes is at least 30%, for example, at least 40%, 50%, 60%, for example, at least 70%, 80%, 90%, 100% of the length of the reference sequence. Then, the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are compared. If a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at this position.

[0235] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences.

[0236] The comparison of sequences and determination of percent identity between two sequences can be achieved using a mathematical algorithm. In one embodiment, the percent identity between two amino acid sequences is determined using the algorithm by Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) incorporated into the GAP program of the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, a gap weight of 16, 14, 12, 10, 8, 6, or 4, and a length weight of 1, 2, 3, 4, 5, or 6. In a specific embodiment, the percent identity between two nucleotide sequences is determined using the GAP program of the GCG software package (available at www.gcg.com), using a NWSgapdna.CMP matrix, a gap weight of 40, 50, 60, 70, or 80, and a length weight of 1, 2, 3, 4, 5, or 6. One suitable parameter set (which should be used unless otherwise specified) is a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4 and a frameshift gap penalty of 5.

[0237] The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm by E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.

[0238] The nucleic acid and protein sequences described herein can be used as a "query sequence" to search public databases, for example, to identify other family members or related sequences. Such searches can be performed using the NBLAST program and the XBLAST program (version 2.0) by Altschul et al. (1990) J. Mol. Biol. 215:403-10. To obtain nucleotide sequences homologous to the nucleic acids described herein, BLAST nucleotide searches can be performed with the NBLAST program, score = 100, word length = 12. To obtain amino acid sequences homologous to the protein molecules described herein, BLAST protein searches can be performed with the XBLAST program, score = 50, word length = 3. To obtain gapped alignments for comparison purposes, gapped BLAST, as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402, can be used. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See ncbi.nlm.nih.gov.

[0239] As used herein, the term "hybridize under low stringency conditions, medium stringency conditions, high stringency conditions or very high stringency conditions" describes the conditions for hybridization and washing.Guidelines for carrying out hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6 (which is incorporated by reference).Aqueous and non-aqueous methods are described in this reference, and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6× sodium chloride / sodium citrate (SSC) at about 45° C., followed by two washes in 0.2× SSC, 0.1% SDS at at least 50° C. (low stringency conditions allow the wash temperature to be increased to 55° C.); 2) 6× SSC at about 45° C., followed by one wash in 0.2× SSC, 0.1% SDS at 60° C. 3) high stringency hybridization conditions in 6×SSC at about 45° C., followed by one additional wash in 0.2×SSC, 0.1% SDS at 65° C.; and preferably 4) ultra-high stringency hybridization conditions in 0.5 M sodium phosphate, 7% SDS at 65° C., followed by one additional wash in 0.2×SSC, 1% SDS at 65° C. Ultra-high stringency condition 4) is the appropriate condition and should be used unless otherwise specified.

[0240] It is understood that the molecules described herein may have additional conservative or non-essential amino acid substitutions that do not have a substantial effect on their function.

[0241] The term "amino acid" is intended to encompass all molecules, whether natural or synthetic, that contain both amino and acid functional groups and can be included in naturally occurring amino acid polymers. Exemplary amino acids include naturally occurring amino acids; their analogs, derivatives, and congeners; amino acid analogs with variant side chains; and all stereoisomers of any of the above. As used herein, the term "amino acid" includes both D- and L-optical isomers and peptidomimetics.

[0242] A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0243] The terms "polypeptide," "peptide," and "protein" (when single chain) are used interchangeably herein to refer to polymers of amino acids of any length. The polymer can be linear or branched, it can contain modified amino acids, and it can be interrupted by non-amino acids. The term also encompasses amino acid polymers that have been modified, such as by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. Polypeptides can be isolated from natural sources, produced by recombinant techniques from eukaryotic or prokaryotic hosts, or can be the product of synthetic procedures.

[0244] As will be recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered within the scope of the present invention. For example, any protein fragment of a reference protein (meaning a polypeptide sequence that is at least one amino acid residue shorter than the reference polypeptide sequence but otherwise identical) having a length of more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 100 amino acids is provided herein. In another example, any protein comprising a stretch of about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 95, about 98%, or about 100% identical to any of the sequences described herein can be utilized in accordance with the present invention. In one embodiment, a protein sequence utilized in accordance with the present disclosure includes 2, 3, 4, 5, 6, 7, 8, 9, 10 or more mutations set forth in any of the sequences provided or referenced herein.

[0245] The terms "nucleic acid," "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence," and "polynucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or their analogs. A polynucleotide can be either single-stranded or double-stranded, and, if single-stranded, can be the coding strand or non-coding (antisense) strand. A polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can be further modified after polymerization, for example, by conjugation with a labeling component. A nucleic acid can be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin, which does not occur in nature or is linked to another polynucleotide in a non-natural configuration.

[0246] As used herein, the term "isolated" refers to material that has been removed from its original or native environment (e.g., the natural environment if it occurs in nature). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide that has been separated from some or all of the coexisting materials in the natural system by human intervention is isolated. Such a polynucleotide may be part of a vector, and / or such a polynucleotide or polypeptide may be part of a composition, but such a vector or composition is still isolated in that it is not part of the environment in which it is found in nature.

[0247] As used herein, the term "treating" a disorder, e.g., myeloma, means that a subject (e.g., a human) having a disorder, e.g., myeloma, and / or experiencing symptoms of the disorder, e.g., myeloma, in one embodiment, suffers less severe symptoms and / or recovers more quickly when the antibody molecule is administered than when the antibody molecule is not administered. In one embodiment, if the myeloma is treated, a bone marrow biopsy will show fewer clonal plasma cells after effective treatment of the myeloma. For example, a diagnostic assay will detect fewer clonal plasma cells in a biological sample of a subject after administration of an antibody molecule described herein for effective treatment of myeloma. Other assays, such as urine tests or blood tests, can also be used to monitor treatment in a patient or to detect the presence, e.g., a decreased presence (or absence), of symptoms of myeloma after treatment of myeloma in a subject. In one embodiment, if the myeloma is treated, the level of β2 microglobulin (β2M) in the serum or urine will decrease after effective treatment of the myeloma. Treatment may, for example, partially or completely alleviate, improve, alleviate, inhibit, or reduce the severity of one or more of the effects or symptoms, characteristics, and / or causes of a disorder, such as myeloma, and / or reduce the incidence, and optionally delay its onset. In one embodiment, treatment is for subjects who do not show specific signs of a disorder, such as myeloma, and / or who show only early signs of a disorder, such as nephropathy. In one embodiment, treatment is for subjects who show one or more established signs of a disorder, such as myeloma. In one embodiment, treatment is for subjects who have been diagnosed with a disorder, such as myeloma.

[0248] As used herein, the term "preventing" a disorder, e.g., myeloma, means that a subject (e.g., a human) is less likely to have the disorder, e.g., myeloma, when the subject is administered the antibody molecule.

[0249] Various aspects of the compositions and methods herein are described in further detail below. Additional definitions are set forth throughout the specification.

[0250] IL-2 agonist The present disclosure provides IL-2 agents, including but not limited to IL-2 variants, IL-2 fusion proteins, IL-2 complexes, and IL-2 conjugates. For example, the IL-2 agents described herein can have one or more structural and / or functional properties described herein. In one embodiment, the IL-2 agent comprises an IL-2 variant comprising one or more amino acid changes (e.g., substitutions) described herein. In one embodiment, the IL-2 agent comprises an IL-2 variant comprising one or more amino acid changes (e.g., substitutions) set forth in Table 9. In one embodiment, the IL-2 agent comprises an IL-2 variant comprising an amino acid sequence set forth in Table 9, or a portion thereof. In one embodiment, the IL-2 agent, or a portion thereof, is encoded by a nucleic acid comprising a nucleotide sequence set forth herein, e.g., in Table 10. One or more amino acid changes (e.g., substitutions), alone or in combination, can confer one or more desired biological properties described herein. In one embodiment, the IL-2 agonist can modulate (e.g., increase) the expansion, survival, activation, and / or function of Tregs. In one embodiment, the modulation is selective or specific for Tregs. For example, the IL-2 agonist can modulate activity in Tregs, but has limited or no ability to promote activity in non-regulatory T cells. In one embodiment, the IL-2 agonist comprises a polypeptide (sometimes referred to herein as an "IL-2 polypeptide agonist").

[0251] IL-2 variants In one embodiment, the IL-2 agent comprises an IL-2 variant, eg, an IL-2 variant described herein.

[0252] In one embodiment, the IL-2 variant comprises an IL-2 polypeptide (e.g., a human IL-2 polypeptide) described herein, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises one or more amino acid changes (e.g., substitutions) described in Table 9. In one embodiment, the IL-2 variant comprises or consists of an amino acid sequence described in Table 9, or a functional fragment thereof. In one embodiment, the IL-2 variant is encoded by a nucleic acid comprising a nucleotide sequence described herein, e.g., in Table 10.

[0253] Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 variants described herein that have reduced human CD25 and / or reduced human CD122 / CD132 binding affinity compared to wild-type human IL-2 or a reference IL-2 variant may have improved potency and / or selectivity for binding to and activating regulatory T cells (Tregs) relative to wild-type IL-2 or other IL-2 variants. The IL-2 variants described herein can be identified, for example, by screening a library of mutated IL-2 polypeptides to identify IL-2 variants that have binding affinity for human CD25 and / or human CD122 / CD132 in the desired range.

[0254] In one embodiment, the IL-2 variant has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more) properties, e.g., different and / or improved properties, described herein, compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid changes (e.g., substitutions) that provide different and / or improved properties compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or all) of the following different and / or improved properties (e.g., as determined by the assays described herein) compared to wild-type IL-2 or a reference IL-2 variant: i) altered (e.g., enhanced or increased) expression in vitro and / or in vivo; ii) altered (e.g., reduced or decreased) aggregation in vitro and / or in vivo; iii) altered (e.g., enhanced or increased) stability in vitro and / or in vivo; iv) altered (e.g., enhanced or increased) half-life in vitro and / or in vivo; v) altered (e.g., slowed or decreased) turnover and / or clearance in vivo; vi) altered (e.g., reduced or decreased) susceptibility to proteolysis in vitro and / or in vivo; vii) altered (e.g., enhanced or increased) resistance to proteolysis in vitro and / or in vivo; viii) altered (e.g., reduced or decreased) binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; ix) altered (e.g., reduced or decreased) binding capacity and / or binding affinity of human CD132 in vitro and / or in vivo; x) altered (e.g., reduced or decreased) binding ability and / or binding affinity to the dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo; xi) altered (e.g., enhanced, increased, decreased, diminished, and / or selective) binding to Tregs in vitro and / or in vivo; xii) altered (e.g., enhanced, increased, decreased, diminished, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo; xiii) Altered (e.g., enhanced, increased, decreased, diminished, and / or selective) ability to induce or promote expansion, activity, survival, and / or proliferation of Tregs in vitro and / or in vivo.

[0255] In one embodiment, the IL-2 variant has altered (e.g., enhanced or increased) expression in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased expression (e.g., in bacteria or mammalian cells) compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased expression (e.g., in bacteria or mammalian cells) compared to a reference IL-2 variant. In one embodiment, expression of the IL-2 variant is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, expression of the IL-2 variant is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 variant is expressed at a higher or increased level in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, compared to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, as determined, e.g., by assaying protein concentration. In one embodiment, the IL-2 variant is expressed at a higher or increased level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more, compared to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, as determined, e.g., by assaying protein concentration.

[0256] In one embodiment, the IL-2 variant has altered (e.g., reduced or decreased) aggregation in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased aggregation compared to wild-type IL-2. In one embodiment, the IL-2 variant has reduced or decreased aggregation compared to a reference IL-2 variant. In one embodiment, aggregation of the IL-2 variant is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, aggregation of the IL-2 variant is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein aggregates at a lower or reduced level in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more reduced aggregation, compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, as determined, for example, by melting temperature analysis (e.g., using fluorescence measurements), dynamic light scattering, and / or size exclusion chromatography. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein aggregates at a lower or reduced level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more reduced aggregation, compared to an IL-2 agent comprising a wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, as determined, for example, by melting temperature analysis (e.g., using fluorescence measurements), dynamic light scattering, and / or size exclusion chromatography.

[0257] In one embodiment, the IL-2 variant has altered (e.g., enhanced or increased) stability in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased stability compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased stability compared to a reference IL-2 variant. In one embodiment, the stability of the IL-2 variant is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the stability of the IL-2 variant is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-variant described herein exhibits enhanced or increased stability in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 121%, about 122%, about 123%, about 124%, about 125%, about 126%, about 127%, about 128%, about 129%, about 130%, about 130%, about 131%, about 132%, about 132, about 133%, about 134%, about The stability may be increased by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0258] In one embodiment, the IL-2 variant has an altered (e.g., enhanced or increased) half-life in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has an enhanced or increased half-life compared to wild-type IL-2. In one embodiment, the IL-2 variant has an enhanced or increased half-life compared to a reference IL-2 variant. In one embodiment, the half-life of the IL-2 variant is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the half-life of the IL-2 variant is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein exhibits an enhanced or increased half-life in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 110%, about 115%, about 120%, about 125%, about 130%, about 135%, about 140%, about 145%, about 150%, about 160%, about 165%, about 170%, about 180%, about 185%, about 190%, about 200%, about 210%, about 215%, about 220%, about 225%, about 230%, about 235%, about 240%, about 245%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, about 500%, about 510%, about 520%, about 530%, about 540%, about 550%, about 560%, about 570%, about 580%, about 590%, about 610%, about 620%, about 6 The half-life may be increased by about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0259] In one embodiment, the IL-2 variant has altered (e.g., reduced or decreased) turnover in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased turnover compared to wild-type IL-2. In one embodiment, the IL-2 variant has reduced or decreased turnover compared to a reference IL-2 variant. In one embodiment, the turnover of the IL-2 variant is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the turnover of the IL-2 variant is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein exhibits a lower, decreased or reduced rate or level of turnover and / or clearance in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, compared to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, as determined, for example, by ELISA, flow cytometry and / or mass spectrometry. , about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or has a rate or level of reduction of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0260] In one embodiment, the IL-2 has altered (e.g., reduced or decreased) susceptibility to proteolysis in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased susceptibility to proteolysis compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 variant has reduced or decreased susceptibility to proteolysis compared to a reference IL-2 variant. In one embodiment, the susceptibility of the IL-2 variant to proteolysis is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the susceptibility of the IL-2 variant to proteolysis is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.

[0261] In one embodiment, the IL-2 variant has altered (e.g., enhanced or increased) resistance to proteolysis in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased resistance to proteolysis compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased resistance to proteolysis compared to a reference IL-2 variant. In one embodiment, the resistance of the IL-2 variant to proteolysis is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the resistance of the IL-2 variant to proteolysis is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.

[0262] In one embodiment, the IL-2 variant has altered (e.g., reduced or decreased) binding ability and / or binding affinity to human CD25 in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased binding ability and / or binding affinity to human CD25 compared to wild-type human IL-2. In one embodiment, the IL-2 variant has reduced or decreased binding ability and / or binding affinity to human CD25 compared to a reference IL-2 variant. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to human CD25 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding capacity and / or binding affinity of the IL-2 variant to human CD25 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, an IL-2 agent comprising an IL-2 variant described herein has a reduced or decreased binding capacity and / or binding affinity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 5 ... or have a binding ability and / or affinity that is reduced by 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0263] In one embodiment, the IL-2 variant has low affinity for CD25 (e.g., human CD25), e.g., about 5 to 500 pM, e.g., about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 ... 5, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, about 250, about 300, about 350, about 400, about 450 or about 500 pM, or for example, about 10 to about 400 pM, about 20 to about 300 pM, about 50 to about 200 pM, about 100 to about 150 pM, about 5 to about 10 pM, for example, about 10 to about 20 pM, about 20 to about 30 pM, or about 30 to about 40 pM, for example, about 40 to about 50 pM, about 50 to about 60 pM, about 60 to about 70 pM, about 70 to about 80 pM, about 80 to about 90 pM, about 90 to about 100 pM, about 100 to about 110 pM, about 110 to about 120 pM, about 120 to about 130 pM, about 130 to about 140 pM, about 140 to about 150 pM, about 150 to about 200 pM, about 200 to about 250 pM, about 250 to about 300 pM, about 300 to about 350 pM, about 350 to about 400 pM, a dissociation constant (K) of about 400 to about 500 pM, or, for example, greater than about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, about 250, about 300, about 350, about 400, about 450, or about 500 pM D ) to join them.

[0264] In one embodiment, the IL-2 variant has low affinity for CD25 (e.g., human CD25), e.g., as determined by surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding), e.g., about 0.1 to 10 nM, e.g., about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, or about 10 nM, or e.g., about 0.2 to about 5 nM, about 0.5 to about 2 nM, about 1 to about 1.5 nM, about 0.1 to about 0.2 nM, e.g., about 0.2 to about 0 0.3 nM, about 0.3 to about 0.4 nM, or about 0.4 to about 0.5 nM, for example, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 1.5 nM, about 1.5 to about 2 nM, about 2.5 to about 3 nM, about 3.5 to about 4 nM, about 4 to about 4.5 nM, about 4 a dissociation constant (K) of greater than about 0.5 to about 5 nM, about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, about 9 to about 10 nM, or, for example, greater than about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 nM D ) to join them.

[0265] In one embodiment, the IL-2 variant has altered (e.g., reduced or decreased) binding ability and / or binding affinity for human CD132 in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has reduced or decreased binding ability and / or binding affinity for human CD132 compared to wild-type IL-2. In one embodiment, the IL-2 variant has reduced or decreased binding ability and / or binding affinity for human CD132 compared to a reference IL-2 variant. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant for human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0266] In one embodiment, the IL-2 variant has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to the human dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has a reduced or decreased binding ability and / or binding affinity to the human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to wild-type IL-2. In one embodiment, the IL-2 variant has a reduced or decreased binding ability and / or binding affinity to the human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to a reference IL-2 variant. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 variant to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0267] In one embodiment, the IL-2 variant has a reduced or decreased binding affinity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, to a CD122 / CD132 heterodimer (e.g., a human CD122 / CD132 heterodimer) compared to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, as determined, for example, by yeast surface display, surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding). , about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more decreased, or have a binding ability and / or binding affinity that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0268] In one embodiment, the IL-2 variant has low affinity for the CD122 / CD132 heterodimer (e.g., human CD122 / CD132 heterodimer), e.g., as determined by yeast surface display, e.g., between about 0.2 and 20 nM, e.g., about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 69, about 70, about 71, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 20 nM, or, for example, about 0.5 to about 15 nM, about 1 to about 10 nM, about 2 to about 5 nM, about 0.2 to about 0.3 nM, about 0.3 to about 0.4 nM, about 0.4 to about 0.5 nM, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 1.1 nM M, about 1.1 to about 1.2 nM, about 1.2 to about 1.3 nM, about 1.3 to about 1.4 nM, about 1.4 to about 1.5 nM, about 1.5 to about 2 nM, about 2 to about 3 nM, about 3 to about 4 nM, about 4 to about 5 nM, about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, about 9 to about 10 nM, about 10 to about 11 nM, about 11 to about 12 nM, about 12 to about 13 nM, about 13 to about 14 nM, about 14 to about 15 nM, about 15 to about 16 nM, about 16 to about 17 nM , about 17 to about 18 nM, about 18 to about 19 nM, or about 19 to about 20 nM, or greater than, for example, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 20 nM.

[0269] In one embodiment, the IL-2 variant has low affinity for CD122 / CD132 heterodimers (e.g., human CD122 / CD132 heterodimers), e.g., about 0.2 to 300 nM, e.g., about 0.2 nM, about 0.5 nM, about 1 nM, about 2 nM, about 5 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, or about 40 nM, as determined, for example, by surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding). nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM or about 300 nM, or for example, about 0.5 to about 15 nM, about 1 to about 10 nM, about 2 to about 5 nM, about 0.2 to about 0.5 nM, about 0.5 to about 1 nM, about 1 to about 2 nM, about 2 to about 5 nM, about 5 to about 10 nM, about 10 to about 15 nM, about 15 to about 20 nM, about 20 to about 25 nM, about 25 to about 30 nM, about 30 to about 40 nM M, about 40 to about 50 nM, about 50 to about 60 nM, about 60 to about 70 nM, about 70 to about 80 nM, about 80 to about 90 nM, about 90 to about 100 nM, about 100 to about 110 nM, about 110 to about 120 nM, about 120 to about 130 nM, about 130 to about 14 0 nM, about 140 to about 150 nM, about 150 to about 160 nM, about 160 to about 170 nM, about 170 to about 180 nM, about 180 to about 190 nM, about 190 to about 200 nM, about 200 to about 210 nM, about 210 to about 220 nM, about 220 to about 230 nM, about 230 to about 240 nM, about 240 to about 250 nM, about 250 to about 260 nM, about 260 to about 270 nM, about 270 to about 280 nM, about 280 to about 290 nM, or about 290 to about 300 nM, or for example, about 0.2, about 0.and binds with a dissociation constant (KD) of greater than 5, about 1, about 2, about 5, about 10, about 15, about 20 nM, about 25 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM, or greater than about 300 nM.

[0270] In one embodiment, the IL-2 variant has altered (e.g., enhanced, increased, and / or selective) binding to Tregs in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased binding to Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has selective binding to Tregs compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 variant has enhanced or increased binding to Tregs compared to a reference IL-2 variant. In one embodiment, the IL-2 variant has selective binding to Tregs compared to a reference IL-2 variant. In one embodiment, binding to Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, binding to Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0271] In one embodiment, the IL-2 variant has altered (e.g., enhanced, increased, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has selective activation of the IL-2 signaling pathway in Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 variant. In one embodiment, the IL-2 variant has selective activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 variant. In one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or about 100% or more, hi one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0272] In one embodiment, the IL-2 variant selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo relative to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, e.g., as determined by flow cytometry, and is at least about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 10 or about 3000.

[0273] In one embodiment, the IL-2 variant selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo relative to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, e.g., about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 750, 800, 850, 900, 950, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7500, 8000, 8500, 9000, 9500, 10 ... 00, 800, 900, 1000, 1500, 2000, 2500 or about 3000 or more, or for example, greater than 1 and about 1-2, about 2-3, about 3-4, about 4-5, greater than 1 and about 1-10, greater than 1 and about 1-20, greater than 1 and about 1-30, greater than 1 and about 1-40, greater than 1 and about 1-50, about 2-10, about 2-20, about 2-30, about 2 about 2 to 50, about 5 to 10, about 5 to 20, about 5 to 30, about 5 to 40, about 5 to 50, about 10 to 20, about 10 to 30, about 10 to 40, about 10 to 50, about 20 to 40, about 20 to 50, about 50 to 100, about 100 to 200, about 200 to 500, about 500 to 1000, about 1000 to 2000, or about 1000 to 3000.

[0274] In one embodiment, the IL-2 variant has an altered (e.g., enhanced, increased, and / or selective) ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs in vitro and / or in vivo compared to wild-type IL-2 or a reference IL-2 variant. In one embodiment, the IL-2 variant has an enhanced or increased ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has a selective ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to wild-type IL-2. In one embodiment, the IL-2 variant has an enhanced or increased ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to a reference IL-2 variant. In one embodiment, the IL-2 variant has a selective ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to a reference IL-2 variant. In one embodiment, the ability to induce or promote expansion, activity, survival and / or proliferation of Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or about 100% or more, hi one embodiment, the ability to induce or promote expansion, activity, survival and / or proliferation of Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0275] In one embodiment, the IL-2 variant has enhanced or increased potency and / or ability to induce or promote regulatory T cell activity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, as determined, e.g., by flow cytometry, compared to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant. , about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more reduced, or has an EC50 for Tregs that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0276] In one embodiment, the IL-2 variant has a reduced or decreased potency and / or ability to induce or promote regulatory T cell activity, as determined by flow cytometry, compared to an IL-2 agent comprising wild-type IL-2 or an IL-2 agent comprising a reference IL-2 variant, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95 ... 0%, about 95%, about 100% or more increased, or have an EC50 for Tregs that is decreased by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold, about 50-fold, about 100-fold, about 200-fold, about 500-fold, about 1000-fold, about 2000-fold, about 5000-fold, about 10,000-fold, about 15,000-fold, about 20,000-fold or more.

[0277] In one embodiment, the T helper cells described herein are CD45+CD3+CD4+Foxp3- cells, e.g., as determined by flow cytometry. In one embodiment, the Tregs described herein are CD45+CD3+CD4+Foxp3+ cells, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3- cells that are CD56+ and / or CD16+, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3-CD56+ cells, e.g., as determined by flow cytometry.

[0278] In one embodiment, the IL-2 variant has one or more structural and / or functional properties that are the same or substantially the same as wild-type IL-2 or a reference IL-2 variant.

[0279] In one embodiment, the reference IL-2 variant comprises an amino acid sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an IL-2 variant described herein. In one embodiment, the reference IL-2 variant comprises the amino acid sequence of SEQ ID NO: 1 (IL-2 C125S). In one embodiment, the IL-2 variant comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO: 1 and that contains one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid changes (e.g., substitutions) described herein.

[0280] For purposes of this disclosure, position numbering for IL-2 variants begins with the first amino acid after the signal peptide of an exemplary wild-type (WT) human IL-2 polypeptide: [ka] The corresponding amino acid sequence without the signal peptide is shown as SEQ ID NO:1031.

[0281] In one embodiment, the IL-2 agonist comprises amino acid alterations (eg, substitutions) at positions corresponding to human IL-2 (eg, comprising the amino acid sequence of SEQ ID NO: 1031).

[0282] In one embodiment, the IL-2 variant is [ka] It contains the amino acid sequence of wherein X3 is T or A, X16 is H, L or N, X28 is I, T or F, X35 is K or E, X38 is R, E, N or Q, X42 is F, A, K or Q, X68 is E, Q or N, X69 is V or A, X74 is Q or P, X84 is D or V, X87 is S or R, X88 is N, D, L or S, X92 is I or S, X125 is C or S, and X126 is Q, K, R or T, with the proviso that the IL-2 variant does not comprise the amino acid sequence of SEQ ID NO: 1 or 1031. In one embodiment, the IL-2 variant comprises or consists of an IL-2 variant amino acid sequence described herein.

[0283] In one embodiment, the IL-2 variant comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) amino acid changes (e.g., substitutions) at a position described herein. In one embodiment, the IL-2 variant comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) amino acid changes (e.g., substitutions) at a position selected from T3, H16, 128, K35, R38, F42, E68, V69, Q74, D84, S87, N88, 192, C125, or Q126.

[0284] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position T3. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position H16. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position I28. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position K35. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position R38. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position F42. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position E68. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position V69. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position Q74. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position D84. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position S87. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position N88. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position I92. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position C125. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position Q126.

[0285] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at positions V69, Q74, or a combination thereof. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at positions V69 and Q74. In one embodiment, the IL-2 variant comprises the amino acid substitution V69A. In one embodiment, the IL-2 variant comprises the amino acid substitution Q74P.

[0286] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position H16, I92, D84, or a combination thereof. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position H16, optionally the amino acid substitution is H16N, H16L, or H16D. In one embodiment, the IL-2 variant comprises the amino acid substitution H16N. In one embodiment, the IL-2 variant comprises the amino acid substitution H16L. In one embodiment, the IL-2 variant comprises the amino acid substitution H16D.

[0287] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position 192, optionally the amino acid substitution is 192S. In one embodiment, the IL-2 variant comprises the amino acid substitution 192S.

[0288] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position D84, optionally the amino acid substitution is D84V. In one embodiment, the IL-2 variant comprises the amino acid substitution D84V.

[0289] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position K35, R38, F42, E68, or a combination thereof. In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position K35, optionally the amino acid substitution is K35E. In one embodiment, the IL-2 variant comprises the amino acid substitution K35E.

[0290] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at position R38, optionally the amino acid substitution is R38E, R38N, or R38Q. In one embodiment, the IL-2 variant comprises the amino acid substitution R38N. In one embodiment, the IL-2 variant comprises the amino acid substitution R38Q.

[0291] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at position F42, optionally the amino acid substitution is F42K or F42Q. In one embodiment, the IL-2 variant comprises the amino acid substitution F42K. In one embodiment, the IL-2 variant comprises the amino acid substitution F42Q.

[0292] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at one, two, or all of: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii) positions H16, 192, or D84. In one embodiment, the IL-2 variant further comprises an amino acid change (e.g., substitution) at one, two, or all of positions R38, F42, or E68.

[0293] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at one, two, or all of: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, or (b) positions R38, F42, or E68.

[0294] In one embodiment, the IL-2 variant contains amino acid changes (e.g., substitutions) at: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii) one, two, or all of (a) positions H16, I92, or D84; and (b) one, two, or all of positions R38, F42, or E68.

[0295] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and H16, optionally the amino acid substitutions are V69A, Q74P, and H16N or H16L, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16N or H16L. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16N. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and H16L.

[0296] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and 192, optionally the amino acid substitutions are V69A, Q74P, and 192S, respectively. In one embodiment, the IL-2 variant comprises the amino acid substitutions V69A, Q74P, and 192S.

[0297] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and D84, optionally the amino acid substitutions are V69A, Q74P, and D84V, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and D84V.

[0298] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and R38, optionally the amino acid substitutions are V69A, Q74P, and R38Q, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and R38Q.

[0299] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and F42, optionally the amino acid substitutions are V69A, Q74P, and F42Q, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and F42Q.

[0300] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and R38, optionally the amino acid substitutions are V69A, Q74P, and R38N, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and R38N.

[0301] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and R38, optionally the amino acid substitutions are V69A, Q74P, and R38E, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and R38E.

[0302] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, K35, and H16, optionally the amino acid substitutions are V69A, Q74P, K35E, and H16N, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, K35E, and H16N.

[0303] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, K35, H16, and R38, optionally the amino acid substitutions are V69A, Q74P, K35E, H16N, and R38N, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, K35E, H16N, and R38N.

[0304] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, H16, and R38, optionally with the amino acid substitutions V69A, Q74P, H16N, and R38N or R38Q, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N, and R38N or R38Q. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N, and R38N. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, H16N, and R38Q.

[0305] In one embodiment, the IL-2 variant comprises an amino acid change (eg, a substitution) at position I28, E68, S87, N88, Q126, or a combination thereof.

[0306] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at position 128, optionally the amino acid substitution is 128T or 128F. In one embodiment, the IL-2 variant comprises the amino acid substitution 128T. In one embodiment, the IL-2 variant comprises the amino acid substitution 128F.

[0307] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at position E68, optionally the amino acid substitution is E68Q or E68N. In one embodiment, the IL-2 variant comprises the amino acid substitution E68Q. In one embodiment, the IL-2 variant comprises the amino acid substitution E68N.

[0308] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position S87, optionally the amino acid substitution is S87 R. In one embodiment, the IL-2 variant comprises the amino acid substitution S87R.

[0309] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at position N88, optionally the amino acid substitution is N88S, N88L, or N88D. In one embodiment, the IL-2 variant comprises the amino acid substitution N88S, N88L, or N88D. In one embodiment, the IL-2 variant comprises the amino acid substitution N88S. In one embodiment, the IL-2 variant comprises the amino acid substitution N88L. In one embodiment, the IL-2 variant comprises the amino acid substitution N88D.

[0310] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., substitution) at position Q126, optionally the amino acid substitution is Q126T, Q126K, or Q126R. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126T, Q126K, or Q126R. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126T. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126K. In one embodiment, the IL-2 variant comprises the amino acid substitution Q126R.

[0311] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position C125, optionally the amino acid substitution is C125S. In one embodiment, the IL-2 variant comprises the amino acid substitution C125S.

[0312] In one embodiment, the IL-2 variant comprises an amino acid change (e.g., a substitution) at position T3, optionally the amino acid substitution is T3A. In one embodiment, the IL-2 variant comprises the amino acid substitution T3A.

[0313] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and C125, optionally the amino acid substitutions are V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions V69A, Q74P, and C125S.

[0314] In one embodiment, the IL-2 variant comprises an amino acid change (eg, a substitution) at position T3, H16, I92, or a combination thereof, optionally the amino acid substitutions are T3A, H16N, and I92S, respectively.

[0315] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions H16, V69, Q74, and C125, optionally the amino acid substitutions are H16N, V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16N, V69A, Q74P, and C125S.

[0316] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions H16, V69, Q74, and C125, optionally the amino acid substitutions are H16L, V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, V69A, Q74P, and C125S.

[0317] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions H16, V69, Q74, 192, and C125, optionally the amino acid substitutions are H16L, V69A, Q74P, 192S, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, V69A, Q74P, 192S, and C125S.

[0318] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions T3, V69, Q74, and C125, optionally the amino acid substitutions are T3A, V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, V69A, Q74P, and C125S.

[0319] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions T3, H16, V69, Q74, and C125, optionally the amino acid substitutions are T3A, H16N or H16L, V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, H16N, V69A, Q74P, and C125S. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, H16L, V69A, Q74P, and C125S.

[0320] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions T3, V69, Q74, I92, and C125, optionally the amino acid substitutions are T3A, V69A, Q74P, I92S, and C125S, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, V69A, Q74P, I92S, and C125S. In one embodiment, the IL-2 variant comprises amino acid substitutions T3A, V69A, Q74P, I92S, and C125S.

[0321] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions H16, K35, V69, and Q74, optionally the amino acid substitutions are H16L, K35E, V69A, and Q74P, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, K35E, V69A, and Q74P.

[0322] In one embodiment, the IL-2 variant comprises amino acid changes (e.g., substitutions) at positions H16, R38, V69A, and Q74P, optionally the amino acid substitutions are H16L, R38Q, V69A, and Q74P, respectively. In one embodiment, the IL-2 variant comprises amino acid substitutions H16L, R38Q, V69A, and Q74P.

[0323] In one embodiment, the IL-2 variant comprises the amino acid substitutions H16L, V69A, Q74P, and C125S. In one embodiment, the IL-2 variant comprises the amino acid substitutions H16N, V69A, Q74P, and C125S.

[0324] There are various technical effects associated with the presence of the particular set of mutations described herein, e.g., a set of mutations comprising an amino acid substitution at position H16 in combination with amino acid substitutions at positions V69, Q74, and C125 (e.g., H16L, V69A, Q74P, and C125S). Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 variants comprising the aforementioned mutations also have reduced binding affinity to CD122 and / or CD132, increasing the potency and selectivity of the IL-2 variant for regulatory T cells (Tregs) compared to other T cell types. Without wishing to be bound by theory, it is also believed that in one embodiment, IL-2 variants comprising the aforementioned mutations are significantly more stable, e.g., due to the presence of the stabilizing V69A and Q74P mutations. For example, it has been unexpectedly discovered that the V69A and Q74P substitutions do not substantially increase the binding affinity of IL-2 variants to CD25, but rather stabilize the IL-2 variants in an active conformation sufficient for binding to CD25. Thus, IL-2 variants containing these mutations selectively activate regulatory T cells (Tregs) and are significantly more stable. Without wishing to be bound by theory, in one embodiment, it is further believed that IL-2 variants containing the aforementioned mutations have reduced or diminished binding ability and / or binding affinity to CD25, thereby improving the longevity of the IL-2 variants. Without wishing to be bound by theory, it is also believed that in one embodiment, IL-2 variants containing these mutations do not substantially promote the expansion, activation, survival, and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo. Without wishing to be bound by theory, in one embodiment, IL-2 variants comprising the aforementioned mutations are further believed to have reduced disulfide mispairing and improved stability due to the presence of, for example, the C125S mutation.In one embodiment, IL-2 agents containing the H16L mutation have reduced binding affinity for CD122 and / or CD132 and / or increased potency and selectivity for Tregs over other T cell types compared to IL-2 agents containing other H16 mutations. These properties make IL-2 variants containing these mutations particularly suitable for treating disorders and conditions resulting from aberrant immune responses, such as autoimmune diseases.

[0325] Thus, in one embodiment, an IL-2 variant (e.g., an IL-2 variant or IL-2 fusion protein) comprising an amino acid substitution at position H16 in combination with amino acid substitutions at positions V69, Q74, and C125 (e.g., H16L, V69A, Q74P, and C125S) has, inter alia, one or more (e.g., two, three, four, five, six, seven, or all) of the following properties compared to wild-type IL-2 or a reference IL-2 variant that does not comprise the amino acid substitution: (i) enhanced or increased stability in vitro or in vivo; (ii) enhanced or increased stability in vitro and / or in vivo in human C16; (iii) reduced or decreased binding capacity and / or affinity for human CD132 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 variant for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased binding capacity and / or affinity for human CD25 in vitro and / or in vivo; (vi) reduced or decreased binding capacity and / or affinity for regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in regulatory T cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote the expansion, activity, survival and / or proliferation of Tregs.

[0326] In one embodiment, the IL-2 variant is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO: or consisting of an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0327] In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 4, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1000, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1001, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0328] In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 4 or 5, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 4, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 5, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 11, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1000, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1001, or a functional fragment thereof. In one embodiment, the IL-2 variant comprises or consists of the amino acid sequence of SEQ ID NO: 1002, or a functional fragment thereof.

[0329] Without wishing to be bound by theory, in one embodiment, it is believed that an IL-2 variant comprising or consisting of the amino acid sequence of SEQ ID NO: 5, or a functional fragment thereof, may have at least one or more of the following advantageous properties: (i) having reduced binding affinity to CD122 and / or CD132, increasing the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) compared to other T cell types; (ii) being significantly stable, e.g., due to the presence of the stabilizing V69A and Q74P mutations; (iii) having reduced or decreased binding capacity and / or binding affinity to CD25, improving the longevity of the IL-2 agent; (iv) not substantially promoting the expansion, activation, survival and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; and / or (v) having reduced disulfide mispairing and improved stability, e.g., due to the presence of the C125S mutation. In one embodiment, an IL-2 agent comprising the H16L mutation has reduced binding affinity for CD122 and / or CD132 and / or increased potency and selectivity for Tregs over other T cell types, compared to IL-2 agents comprising other H16 mutations. These properties make an IL-2 variant comprising or consisting of the amino acid sequence of SEQ ID NO:5 particularly suitable for the treatment of disorders and conditions resulting from an aberrant immune response, such as autoimmune diseases.

[0330] Thus, in one embodiment, an IL-2 variant comprising or consisting of the amino acid sequence SEQ ID NO: 5, or a functional fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or differing by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 or fewer amino acids thereto, has, inter alia, one or more (e.g., 2, 3, 4, 5, 6, 7, or all) of the following properties compared to wild-type IL-2 or a reference IL-2 variant that does not contain the amino acid substitutions: (i) exhibits a specific activity in vitro or in vivo. (ii) reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 variant to the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased, or substantially unchanged, binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) reduced or decreased, or substantially unchanged, binding capacity and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in regulatory T cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote the expansion, activity, survival and / or proliferation of Tregs.

[0331] As further described herein, the present disclosure provides IL-2 fusion proteins, IL-2 complexes, and IL-2 conjugates that include the IL-2 variants described herein. In one embodiment, one or more different and / or improved properties ascribed to the IL-2 variants described herein are maintained, transferred, or conferred to the IL-2 fusion protein, IL-2 complex, or IL-2. For purposes of this disclosure, the terms "IL-2 variant" and "IL-2 mutein" may be used interchangeably herein.

[0332] In one embodiment, the IL-2 variant comprises a polypeptide (sometimes referred to herein as an "IL-2 variant polypeptide"). The present disclosure provides isolated nucleic acid molecules encoding the IL-2 variants described herein, as well as vectors and host cells thereof. Nucleic acid molecules include, but are not limited to, RNA, genomic DNA, and cDNA.

[0333] IL-2 fusion protein In one embodiment, the IL-2 agent comprises an IL-2 fusion protein, such as an IL-2 fusion protein described herein.

[0334] In one embodiment, the IL-2 fusion protein comprises an IL-2 variant, e.g., an IL-2 variant described herein. In one embodiment, the IL-2 fusion protein comprises one or more amino acid changes (e.g., substitutions) set forth in Table 9. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence set forth in Table 9, or a functional fragment thereof. In one embodiment, the IL-2 variant is encoded by a nucleic acid comprising a nucleotide sequence set forth herein, e.g., in Table 10.

[0335] Without wishing to be bound by theory, in one embodiment, it is believed that IL-2 fusion proteins described herein that have reduced human CD25 and / or reduced human CD122 / CD132 binding affinity compared to IL-2 fusion proteins comprising wild-type human IL-2 or reference IL-2 fusion proteins may have improved potency and / or selectivity for binding to and activating regulatory T cells (Tregs) over IL-2 fusion proteins comprising wild-type IL-2 or other IL-2 fusion proteins.

[0336] In one embodiment, the IL-2 fusion protein has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more) properties, e.g., different and / or improved properties, described herein, compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein includes one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid changes (e.g., substitutions) that provide different and / or improved properties compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or all) of the following different and / or improved properties (e.g., as determined by the assays described herein) compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein: i) altered (e.g., enhanced or increased) expression in vitro and / or in vivo; ii) altered (e.g., reduced or decreased) aggregation in vitro and / or in vivo; iii) altered (e.g., enhanced or increased) stability in vitro and / or in vivo; iv) altered (e.g., enhanced or increased) half-life in vitro and / or in vivo; v) altered (e.g., slowed or decreased) turnover and / or clearance in vivo; vi) altered (e.g., reduced or decreased) susceptibility to proteolysis in vitro and / or in vivo; vii) altered (e.g., enhanced or increased) resistance to proteolysis in vitro and / or in vivo; viii) altered (e.g., reduced or decreased) binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; ix) altered (e.g., reduced or decreased) binding capacity and / or binding affinity of human CD132 in vitro and / or in vivo; x) altered (e.g., reduced or decreased) binding ability and / or binding affinity to the dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo; xi) altered (e.g., enhanced, increased, decreased, diminished, and / or selective) binding to Tregs in vitro and / or in vivo; xii) altered (e.g., enhanced, increased, decreased, diminished, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo; xiii) Altered (e.g., enhanced, increased, decreased, diminished, and / or selective) ability to induce or promote expansion, activity, survival, and / or proliferation of Tregs in vitro and / or in vivo.

[0337] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced or increased) expression in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased expression (e.g., in bacteria or mammalian cells) compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased expression (e.g., in bacteria or mammalian cells) compared to a reference IL-2 fusion protein. In one embodiment, expression of the IL-2 fusion protein is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, expression of the IL-2 fusion protein is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein is expressed at a higher or increased level in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined, e.g., by assaying protein concentration. In one embodiment, the IL-2 fusion protein is expressed at a higher or increased level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more, compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined, e.g., by an assay of protein concentration.

[0338] In one embodiment, the IL-2 fusion protein has altered (e.g., lowered or decreased) aggregation in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has lowered or decreased aggregation compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has lowered or decreased aggregation compared to a reference IL-2 fusion protein. In one embodiment, aggregation of the IL-2 fusion protein is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, aggregation of the IL-2 fusion protein is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein aggregates at a lower or reduced level in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more reduced aggregation, compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined, for example, by melting temperature analysis (e.g., using fluorescence measurements), dynamic light scattering, and / or size exclusion chromatography. In one embodiment, the IL-2 fusion protein aggregates at a lower or reduced level, e.g., about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more reduced aggregation, compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined, for example, by melting temperature analysis (e.g., using fluorescence measurements), dynamic light scattering and / or size exclusion chromatography.

[0339] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced or increased) stability in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased stability compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased stability compared to a reference IL-2 fusion protein. In one embodiment, the stability of the IL-2 fusion protein is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the stability of the IL-2 fusion protein is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has enhanced or increased stability in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 45%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 95%, about 100%, about 105%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 121%, about 122%, about 123%, about 124%, about 125%, about 126%, about 127%, about 128%, about 129%, about 130%, about 131%, about 132%, about 133%, about 134%, about 135%, about 136%, about 137%, about 138%, about 139%, about 140%, about 141%, about 142%, about 143%, about 144%, about 145%, about 146%, about 147%, about 148%, about 149%, about 150%, about 151%, about 152%, about 153%, about 154%, about 155%, about 156%, about 157%, about 158%, about 159%, about 160%, about 161%, about 162%, about 163%, about 164%, about 165%, about 1 0%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more increased stability, or for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more increased stability.

[0340] In one embodiment, the IL-2 fusion protein has an altered (e.g., enhanced or increased) half-life in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has an enhanced or increased half-life compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has an enhanced or increased half-life compared to a reference IL-2 fusion protein. In one embodiment, the half-life of the IL-2 fusion protein is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the half-life of the IL-2 fusion protein is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has an enhanced or increased half-life in vitro and / or in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 5 ... The half-life may be increased by 5%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0341] In one embodiment, the IL-2 fusion protein has altered (e.g., lowered or decreased) metabolic turnover in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has lowered or decreased metabolic turnover compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has lowered or decreased metabolic turnover compared to a reference IL-2 fusion protein. In one embodiment, the metabolic turnover of the IL-2 fusion protein is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the metabolic turnover of the IL-2 fusion protein is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein exhibits a lower, decreased or reduced rate or level of turnover and / or clearance in vivo, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 121%, about 122%, about 123%, about 124%, about 125%, about 126%, about 127%, about 128%, about 129%, about 130%, about 131%, about 132%, about 133%, about 134%, about 135%, about 136%, about A decrease of 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or having a rate or level of decrease of, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0342] In one embodiment, the IL-2 fusion proteins provided by the present disclosure comprise the property of having altered (e.g., reduced or decreased) susceptibility to proteolysis in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has reduced or decreased susceptibility to proteolysis compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 fusion protein has reduced or decreased susceptibility to proteolysis compared to a reference IL-2 fusion protein. In one embodiment, the susceptibility of the IL-2 fusion protein to proteolysis is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the susceptibility of the IL-2 fusion protein to proteolysis is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0343] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced or increased) resistance to proteolysis in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased resistance to proteolysis compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased resistance to proteolysis compared to a reference IL-2 fusion protein. In one embodiment, the resistance of the IL-2 fusion protein to proteolysis is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the resistance of the IL-2 fusion protein to proteolysis is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.

[0344] In one embodiment, the IL-2 fusion protein has altered (e.g., reduced or decreased) binding ability and / or binding affinity for human CD25 in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has reduced or decreased binding ability and / or binding affinity for human CD25 compared to wild-type human IL-2. In one embodiment, the IL-2 fusion protein has reduced or decreased binding ability and / or binding affinity for human CD25 compared to a reference IL-2 fusion protein. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein for human CD25 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to human CD25 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, to CD25 (e.g., human CD25) compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined, for example, by yeast surface display, surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding). , about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more decreased, or have a binding ability and / or binding affinity that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0345] In one embodiment, the IL-2 fusion protein has low affinity for CD25 (e.g., human CD25), e.g., about 5 to 500 pM, e.g., about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 210, about 220, about 230, about 240, about 250, about 260, about 270, about 280, about 290, about 310, about 320, about 330, about 340, about 350, about 360, about 370, about 380, about 390, about 410, about 420, about 430, about 440, about 450, about 460, about 470, about 480, about 490, about 510, about 520, about 530, about 540, about 550, about 560, about 570, about 580, about 590, about 610, about 620, about 630, about 640, about 650, about 660, about 670, about 680, about 700, about 710, about 720, about 730, about 740, about 750, about 760, about 770, about 780, about 7 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, about 250, about 300, about 350, about 400, about 450, or about 500 pM, or, for example, about 10 to about 400 pM, about 20 to about 300 pM, about 50 to about 200 pM, about 100 to about 150 pM, about 5 to about 10 pM, for example, about 10 to about 20 pM, about 20 to about 30 pM , or about 30 to about 40 pM, for example, about 40 to about 50 pM, about 50 to about 60 pM, about 60 to about 70 pM, about 70 to about 80 pM, about 80 to about 90 pM, about 90 to about 100 pM, about 100 to about 110 pM, about 110 to about 120 pM, about 120 to about 130 pM, about 130 to about 140 pM, about 140 to about 150 pM, about 150 to about 200 pM, about 200 to about 250 pM, about 250 to about 300 pM, about 300 to about 350 pM, about 350 to about 400 pM , about 400 to about 500 pM, or greater than, for example, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 200, about 250, about 300, about 350, about 400, about 450, or about 500 pM. D ) to join them.

[0346] In one embodiment, the IL-2 fusion protein has low affinity for CD25 (e.g., human CD25), e.g., as determined by surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding), for example, about 0.1 to 10 nM, e.g., about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 6, about 7, about 8, about 9, or about 10 nM, or for example, about 0.2 to about 5 nM, about 0.5 to about 2 nM, about 1 to about 1.5 nM, about 0.1 to about 0.2 nM, e.g., about 0.2 to about 0.3 nM, about 0.3 to about 0.4 nM, or about 0.4 to about 0.5 nM, for example, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 1.5 nM, about 1.5 to about 2 nM, about 2.5 to about 3 nM, about 3.5 to about 4 nM, about 4 to about 4.5 nM, about a dissociation constant (K) of 4.5 to about 5 nM, about 5 to about 6 nM, about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, about 9 to about 10 nM, or greater than, for example, about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 nM D ) to join them.

[0347] In one embodiment, the IL-2 fusion protein has altered (e.g., reduced or decreased) binding ability and / or binding affinity for human CD132 in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has reduced or decreased binding ability and / or binding affinity for human CD132 compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has reduced or decreased binding ability and / or binding affinity for human CD132 compared to a reference IL-2 fusion protein. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein for human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0348] In one embodiment, the IL-2 fusion protein has an altered (e.g., reduced or decreased) binding ability and / or binding affinity to a human dimeric IL-2 receptor comprising human CD122 and human CD132 in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to a human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has a reduced or decreased binding ability and / or binding affinity to a human dimeric IL-2 receptor comprising human CD122 and human CD132 compared to a reference IL-2 fusion protein. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, the binding ability and / or binding affinity of the IL-2 fusion protein to a human dimeric IL-2 receptor comprising human CD122 and human CD132 is reduced by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or about 10-fold or more.

[0349] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced, increased, and / or selective) binding to Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, binding to Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, binding to Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0350] In one embodiment, the IL-2 fusion protein has a reduced or decreased binding affinity, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 35%, about 40%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 110%, about 115%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, about 500%, about 510%, about 520%, about 530%, about 540%, about 550%, about 560%, about 570%, about 580%, about 590%, about 610%, about 620%, about 630%, about 640%, about 650%, about 660%, about 670%, about 680%, about 690%, about 700%, about 710%, about 720%, about 730%, about 740%, about 750%, or have a binding ability and / or affinity that is reduced by 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0351] In one embodiment, the IL-2 fusion protein has low affinity for the CD122 / CD132 heterodimer (e.g., human CD122 / CD132 heterodimer), e.g., about 0.2 to 20 nM, e.g., about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 69, about 70, about 71, about 72, about 73, about , about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 20 nM, or for example, about 0.5 to about 15 nM, about 1 to about 10 nM, about 2 to about 5 nM, about 0.2 to about 0.3 nM, about 0.3 to about 0.4 nM, about 0.4 to about 0.5 nM, about 0.5 to about 0.6 nM, about 0.6 to about 0.7 nM, about 0.7 to about 0.8 nM, about 0.8 to about 0.9 nM, about 0.9 to about 1 nM, about 1 to about 20 nM, or Approximately 1.1nM, approximately 1.1 to approximately 1.2nM, approximately 1.2 to approximately 1.3nM, approximately 1.3 to approximately 1.4nM, approximately 1.4 to approximately 1.5nM, approximately 1.5 to approximately 2nM, approximately 2 to approximately 3nM, approximately 3 to approximately 4nM, approximately 4 to approximately 5nM, approximately 5 to approximately 6nM , about 6 to about 7 nM, about 7 to about 8 nM, about 8 to about 9 nM, about 9 to about 10 nM, about 10 to about 11 nM, about 11 to about 12 nM, about 12 to about 13 nM, about 13 to about 14 nM, about 14 to about 15 nM, about 15 to about 16 nM, about 16 a dissociation constant (K) of greater than about 17 nM, about 17 to about 18 nM, about 18 to about 19 nM, or about 19 to about 20 nM, or greater than, for example, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, or about 20 nM D ) to join them.

[0352] In one embodiment, the IL-2 fusion protein has low affinity for the CD122 / CD132 heterodimer (e.g., human CD122 / CD132 heterodimer), e.g., about 0.2 to 300 nM, e.g., about 0.2 nM, about 0.5 nM, about 1 nM, about 2 nM, about 5 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, or about 40 nM, as determined, for example, by surface plasmon resonance (e.g., Biacore) and / or biolayer interferometry (e.g., Octet binding). 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM or about 300 nM, or for example, about 0.5 to about 15 nM, about 1 to about 1 0nM, about 2 to about 5nM, about 0.2 to about 0.5nM, about 0.5 to about 1nM, about 1 to about 2nM, about 2 to about 5nM, about 5 to about 10nM, about 10 to about 15nM, about 15 to about 20nM, about 20 to about 25nM, about 25 to about 30nM, about 30 to about 40n M, about 40 to about 50 nM, about 50 to about 60 nM, about 60 to about 70 nM, about 70 to about 80 nM, about 80 to about 90 nM, about 90 to about 100 nM, about 100 to about 110 nM, about 110 to about 120 nM, about 120 to about 130 nM, about 130 to about 14 0 nM, about 140 to about 150 nM, about 150 to about 160 nM, about 160 to about 170 nM, about 170 to about 180 nM, about 180 to about 190 nM, about 190 to about 200 nM, about 200 to about 210 nM, about 210 to about 220 nM, about 220 to about 230 nM, about 230 to about 240 nM, about 240 to about 250 nM, about 250 to about 260 nM, about 260 to about 270 nM, about 270 to about 280 nM, about 280 to about 290 nM, or about 290 to about 300 nM, or for example, about 0.2, about 0.a dissociation constant (K.sub.i) of greater than 5, about 1, about 2, about 5, about 10, about 15, about 20 nM, about 25 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 110 nM, about 120 nM, about 130 nM, about 140 nM, about 150 nM, about 160 nM, about 170 nM, about 180 nM, about 190 nM, about 200 nM, about 210 nM, about 220 nM, about 230 nM, about 240 nM, about 250 nM, about 260 nM, about 270 nM, about 280 nM, about 290 nM, or greater than about 300 nM; D ) to join them.

[0353] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced, increased, and / or selective) binding to Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to IL-2 (e.g., wild-type human IL-2). In one embodiment, the IL-2 fusion protein has enhanced or increased binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has selective binding to Tregs compared to a reference IL-2 fusion protein. In one embodiment, binding to Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or about 100% or more. In one embodiment, binding to Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0354] In one embodiment, the IL-2 fusion protein has altered (e.g., enhanced, increased, and / or selective) activation of the IL-2 signaling pathway in Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has selective activation of the IL-2 signaling pathway in Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has enhanced or increased activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has selective activation of the IL-2 signaling pathway in Tregs compared to a reference IL-2 fusion protein. In one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or about 100% or more, hi one embodiment, activation of the IL-2 signaling pathway in Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0355] In one embodiment, the IL-2 fusion protein selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo relative to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, e.g., as determined by flow cytometry, e.g., about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 , 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500 or about 3000.

[0356] In one embodiment, the IL-2 fusion protein selectively activates IL-2 signaling in T regulatory cells in vitro and / or in vivo relative to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, e.g., as determined by flow cytometry, e.g., about 1, about 2, about 3, about 4, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700 , 800, 900, 1000, 1500, 2000, 2500 or about 3000 or more, or for example, greater than 1 and about 1-2, about 2-3, about 3-4, about 4-5, greater than 1 and about 1-10, greater than 1 and about 1-20, greater than 1 and about 1-30, greater than 1 and about 1-40, greater than 1 and about 1-50, about 2-10, about 2-20, about 2-30, about 2- 40, about 2 to 50, about 5 to 10, about 5 to 20, about 5 to 30, about 5 to 40, about 5 to 50, about 10 to 20, about 10 to 30, about 10 to 40, about 10 to 50, about 20 to 40, about 20 to 50, about 50 to 100, about 100 to 200, about 200 to 500, about 500 to 1000, about 1000 to 2000, or about 1000 to 3000.

[0357] In one embodiment, the IL-2 fusion protein has an altered (e.g., enhanced, increased, and / or selective) ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs in vitro and / or in vivo compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has an enhanced or increased ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has a selective ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to an IL-2 fusion protein comprising wild-type IL-2. In one embodiment, the IL-2 fusion protein has an enhanced or increased ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to a reference IL-2 fusion protein. In one embodiment, the IL-2 fusion protein has a selective ability to induce or promote the expansion, activity, survival, and / or proliferation of Tregs compared to a reference IL-2 fusion protein. In one embodiment, the ability to induce or promote expansion, activity, survival and / or proliferation of Tregs is increased by about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or about 100% or more, hi one embodiment, the ability to induce or promote expansion, activity, survival and / or proliferation of Tregs is increased by about 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or about 10-fold or more.

[0358] In one embodiment, the IL-2 fusion protein has enhanced or increased potency and / or ability to induce or promote regulatory T cell activity compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, e.g., as determined by flow cytometry, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about or has an EC50 for Tregs that is reduced by 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100% or more, or that is reduced by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold or more.

[0359] In one embodiment, the IL-2 fusion protein has a reduced or decreased potency and / or ability to induce or promote regulatory T cell activity compared to an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein, as determined by flow cytometry, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90% , about 95%, about 100% or more increased, or has an EC50 for Tregs that is decreased by, for example, about 0.5-fold, about 1-fold, about 1.5-fold, about 2-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, about 5-fold, about 5.5-fold, about 6-fold, about 6.5-fold, about 7-fold, about 7.5-fold, about 8-fold, about 8.5-fold, about 9-fold, about 9.5-fold, about 10-fold, about 50-fold, about 100-fold, about 200-fold, about 500-fold, about 1000-fold, about 2000-fold, about 5000-fold, about 10,000-fold, about 15,000-fold, about 20,000-fold or more.

[0360] In one embodiment, the T helper cells described herein are CD45+CD3+CD4+Foxp3- cells, e.g., as determined by flow cytometry. In one embodiment, the Tregs described herein are CD45+CD3+CD4+Foxp3+ cells, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3- cells that are CD56+ and / or CD16+, e.g., as determined by flow cytometry. In one embodiment, the NK cells described herein are CD45+CD3-CD56+ cells, e.g., as determined by flow cytometry.

[0361] In one embodiment, the IL-2 fusion protein has one or more structural and / or functional properties that are the same or substantially the same as an IL-2 fusion protein comprising wild-type IL-2 or a reference IL-2 fusion protein.

[0362] In one embodiment, the reference IL-2 fusion protein comprises an amino acid sequence having about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to an IL-2 fusion protein described herein. In one embodiment, the reference IL-2 fusion protein comprises an IL-2 variant comprising the amino acid sequence of SEQ ID NO: 57. In one embodiment, the IL-2 fusion protein comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO: 57 and that contains one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid changes (e.g., substitutions) described herein.

[0363] In one embodiment, the IL-2 fusion protein comprises an IL-2 polypeptide (e.g., a human IL-2 polypeptide) described herein. In one embodiment, the IL-2 fusion protein is encoded by a nucleic acid comprising a nucleotide sequence described herein.

[0364] In one embodiment, the IL-2 fusion protein comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) amino acid changes (e.g., substitutions) at a position in IL-2 described herein. In one embodiment, the IL-2 fusion protein comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all) amino acid changes (e.g., substitutions) at a position selected from T3, H16, 128, K35, R38, F42, E68, V69, Q74, D84, S87, N88, 192, C125, or Q126.

[0365] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position T3 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position H16 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position I28 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position K35 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position R38 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position F42 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position E68 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position V69 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position Q74 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position D84 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position S87 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position N88 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position I92 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position C125 in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position Q126 in IL-2.

[0366] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at positions V69, Q74, or both in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at positions V69 and Q74 in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution V69A in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q74P in IL-2.

[0367] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position H16, I92, D84, or both in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position H16, optionally the amino acid substitution is H16N, H16L, or H16D in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution H16N in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution H16L in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution H16D in IL-2.

[0368] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., substitution) at position 192, optionally the amino acid substitution is 192S in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution 192S in IL-2.

[0369] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position D84, optionally the amino acid substitution is D84V in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution D84V in IL-2.

[0370] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position K35, R38, F42, E68, or a combination thereof in IL-2. In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position K35, optionally the amino acid substitution is K35E in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution K35E in IL-2.

[0371] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., substitution) at position R38, optionally the amino acid substitution is R38E, R38N, or R38Q in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution R38N in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution R38Q in IL-2.

[0372] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position F42, optionally the amino acid substitution is F42K or F42Q in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution F42K in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution F42Q in IL-2.

[0373] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at one, two, or all of the following in IL-2: (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35; and (ii) positions H16, 192, or D84. In one embodiment, the IL-2 fusion protein further comprises amino acid changes (e.g., substitutions) at one, two, or all of the following positions R38, F42, or E68 in IL-2.

[0374] In one embodiment, the IL-2 fusion protein contains amino acid changes (e.g., substitutions) in IL-2 at (i)(a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii)(a) one, two, or all of positions H16, I92, or D84; or (b) one, two, or all of positions R38, F42, or E68.

[0375] In one embodiment, the IL-2 fusion protein contains amino acid changes (e.g., substitutions) in IL-2 at (i) (a) positions V69 and Q74, (b) position K35, or (c) positions V69, Q74, and K35, and (ii) one, two, or all of (a) positions H16, I92, or D84; and (b) one, two, or all of positions R38, F42, or E68.

[0376] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and H16, optionally the amino acid substitutions are V69A, Q74P, and H16N or H16L, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16N or H16L in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16N in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and H16L in IL-2.

[0377] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and 192, optionally the amino acid substitutions are V69A, Q74P, and 192S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and 192S in IL-2.

[0378] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and D84, optionally the amino acid substitutions are V69A, Q74P, and D84V, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and D84V in IL-2.

[0379] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and R38, optionally the amino acid substitutions are V69A, Q74P, and R38Q, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and R38Q in IL-2.

[0380] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and F42, optionally the amino acid substitutions are V69A, Q74P, and F42Q, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and F42Q in IL-2.

[0381] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and R38, optionally the amino acid substitutions are V69A, Q74P, and R38N, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and R38N in IL-2.

[0382] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and R38, optionally the amino acid substitutions are V69A, Q74P, and R38E, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and R38E in IL-2.

[0383] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, K35, and H16, optionally the amino acid substitutions are V69A, Q74P, K35E, and H16N, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, K35E, and H16N in IL-2.

[0384] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, K35, H16, and R38, optionally the amino acid substitutions are V69A, Q74P, K35E, H16N, and R38N, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, K35E, H16N, and R38N in IL-2.

[0385] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, H16, and R38, optionally the amino acid substitutions are V69A, Q74P, H16N, and R38N or R38Q in IL-2, respectively. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N, and R38N or R38Q in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N, and R38N in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, H16N, and R38Q in IL-2.

[0386] In one embodiment, the IL-2 fusion protein comprises an amino acid change (eg, a substitution) at position 128, E68, S87, N88, Q126, or a combination thereof in IL-2.

[0387] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., substitution) at position 128, optionally the amino acid substitution is 128T or 128F in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution 128T in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution 128F in IL-2.

[0388] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position E68, optionally the amino acid substitution is E68Q or E68N in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution E68Q in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution E68N in IL-2.

[0389] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position S87, optionally the amino acid substitution is S87R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution S87R in IL-2.

[0390] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., substitution) at position N88, optionally the amino acid substitution is N88S, N88L, or N88D in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88S, N88L, or N88D in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88S in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88L in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution N88D in IL-2.

[0391] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position Q126, optionally the amino acid substitution is Q126T, Q126K, or Q126R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126T, Q126K, or Q126R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126T, Q126K, or Q126R in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126T in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126K in IL-2. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution Q126R in IL-2.

[0392] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position C125 in IL-2, optionally the amino acid substitution is C125S. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution C125S in IL-2.

[0393] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position T3 in IL-2, optionally the amino acid substitution is T3A. In one embodiment, the IL-2 fusion protein comprises the amino acid substitution T3A in IL-2.

[0394] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions V69, Q74, and C125 in IL-2, optionally the amino acid substitutions are V69A, Q74P, and C125S, respectively. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions V69A, Q74P, and C125S in IL-2.

[0395] In one embodiment, the IL-2 fusion protein comprises an amino acid change (e.g., a substitution) at position T3, H16, I92, or a combination thereof in IL-2, optionally the amino acid substitutions are T3A, H16N, and I92S, respectively, in IL-2.

[0396] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions H16, V69, Q74, and C125 in IL-2, optionally the amino acid substitutions are H16N, V69A, Q74P, and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16N, V69A, Q74P, and C125S in IL-2.

[0397] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions H16, V69, Q74, and C125 in IL-2, optionally the amino acid substitutions are H16L, V69A, Q74P, and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, V69A, Q74P, and C125S in IL-2.

[0398] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions H16, V69, Q74, 192, and C125 in IL-2, optionally the amino acid substitutions are H16L, V69A, Q74P, 192S, and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, V69A, Q74P, 192S, and C125S in IL-2.

[0399] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions T3, V69, Q74, and C125 in IL-2, optionally the amino acid substitutions are T3A, V69A, Q74P, and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, V69A, Q74P, and C125S in IL-2.

[0400] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions T3, H16, V69, Q74, and C125 in IL-2, optionally the amino acid substitutions are T3A, H16N or H16L, V69A, Q74P, and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, H16N, V69A, Q74P, and C125S. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, H16L, V69A, Q74P, and C125S in IL-2.

[0401] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions T3, V69, Q74, 192, and C125 in IL-2, optionally the amino acid substitutions are T3A, V69A, Q74P, 192S, and C125S, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, V69A, Q74P, 192S, and C125S in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions T3A, V69A, Q74P, 192S, and C125S in IL-2.

[0402] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions H16, K35, V69, and Q74, optionally the amino acid substitutions are H16L, K35E, V69A, and Q74P, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, K35E, V69A, and Q74P in IL-2.

[0403] In one embodiment, the IL-2 fusion protein comprises amino acid changes (e.g., substitutions) at positions H16, R38, V69A, and Q74P, optionally the amino acid substitutions are H16L, R38Q, V69A, and Q74P, respectively, in IL-2. In one embodiment, the IL-2 fusion protein comprises amino acid substitutions H16L, R38Q, V69A, and Q74P in IL-2.

[0404] In one embodiment, the IL-2 fusion protein comprises the amino acid substitutions H16L, V69A, Q74P, and C125S in IL-2.

[0405] Without wishing to be bound by theory, in one embodiment, it is believed that an IL-2 fusion protein comprising the amino acid substitutions H16L, V69A, Q74P, and C125S may have at least one or more of the following advantageous properties: (i) reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) relative to other T cell types; (ii) significantly stable, e.g., due to the presence of the stabilizing V69A and Q74P mutations; (iii) reduced or decreased binding capacity and / or binding affinity for CD25, improving the longevity of the IL-2 agent; (iv) not substantially promoting the expansion, activation, survival, and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; and / or (v) reduced disulfide mispairing and improved stability, e.g., due to the presence of the C125S mutation. In one embodiment, an IL-2 agent comprising the H16L mutation has reduced binding affinity to CD122 and / or CD132 and / or increased potency and selectivity for Tregs over other T cell types compared to IL-2 agents comprising other H16 mutations. These properties make IL-2 variants comprising the amino acid substitutions H16L, V69A, Q74P, and C125S particularly suitable for the treatment of disorders and conditions resulting from an aberrant immune response, such as autoimmune diseases.

[0406] Thus, in one embodiment, an IL-2 fusion protein comprising the amino acid substitutions H16L, V69A, Q74P, and C125S has, inter alia, one or more (e.g., two, three, four, five, six, seven, or all) of the following properties compared to wild-type IL-2 or a reference IL-2 variant that does not comprise the amino acid substitutions: (i) enhanced or increased stability in vitro or in vivo; (ii) reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 variant for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased or substantially unchanged binding ability and / or binding affinity for human CD25 in vitro and / or in vivo; (vi) reduced or decreased or substantially unchanged binding ability and / or binding affinity for regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in regulatory T cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote the expansion, activity, survival and / or proliferation of Tregs.

[0407] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO and IL-2 variants comprising an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0408] In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 4, or an IL-2 variant comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 5, or an IL-2 variant comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 11, or an IL-2 variant comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1000, or an IL-2 variant comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1001, or an IL-2 variant comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1002, or an IL-2 variant comprising an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0409] In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of any of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 4 or 5, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 4, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 5, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises or consists of the amino acid sequence of SEQ ID NO: 11, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1000, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1001, or a functional fragment thereof. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1002, or a functional fragment thereof.

[0410] Without wishing to be bound by theory, in one embodiment, it is believed that an IL-2 fusion protein comprising the amino acid sequence of SEQ ID NO: 5, or a functional fragment thereof, may have at least one or more of the following advantageous properties: (i) reduced binding affinity to CD122 and / or CD132, increasing the potency and selectivity of the IL-2 agent for regulatory T cells (Tregs) compared to other T cell types; (ii) significantly stable, e.g., due to the presence of the stabilizing V69A and Q74P mutations; (iii) reduced or decreased binding capacity and / or binding affinity to CD25, improving the longevity of the IL-2 agent; (iv) not substantially promoting the expansion, activation, survival, and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; and / or (v) reduced disulfide mispairing and improved stability, e.g., due to the presence of the C125S mutation. In one embodiment, an IL-2 agent comprising the H16L mutation has reduced binding affinity for CD122 and / or CD132 and / or increased potency and selectivity for Tregs over other T cell types compared to IL-2 agents comprising other H16 mutations. These properties make IL-2 fusion proteins comprising the amino acid sequence of SEQ ID NO:5 particularly suitable for the treatment of disorders and conditions resulting from an aberrant immune response, such as autoimmune diseases.

[0411] Thus, in one embodiment, an IL-2 fusion protein comprising the amino acid sequence SEQ ID NO:5, or a functional fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or which differs by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 or fewer amino acids thereto, possesses, inter alia, one or more (e.g., 2, 3, 4, 5, 6, 7, or all) of the following properties compared to wild-type IL-2 or a reference IL-2 fusion protein that does not contain the amino acid substitutions: (i) enhanced or in vitro or in vivo activity; (ii) reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 fusion protein to the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased, or substantially unchanged, binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) reduced or decreased, or substantially unchanged, binding capacity and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in regulatory T cells (Tregs) in vitro or in vivo; or (viii) enhanced or increased ability to induce or promote the expansion, activity, survival and / or proliferation of Tregs.

[0412] In one embodiment, an IL-2 fusion protein described herein comprises an Fc region, e.g., an Fc region having one or more mutations described herein and / or having one or more structural or functional properties described herein. Without wishing to be bound by theory, in one embodiment, it is believed that the Fc region described herein can reduce (e.g., prevent) renal clearance and / or extend half-life of an IL-2 agonist (e.g., via FcRn).

[0413] As used herein, the term "fusion protein" refers to a protein comprising two or more protein or peptide components. The two or more protein or peptide components may be obtained from different sources or encoded by different genes. Fusion proteins are sometimes referred to as chimeric proteins. An Fc fusion protein (also known as an Fc chimeric fusion protein, Fc-Ig, Ig-based chimeric fusion protein, or Fc tag protein) may comprise an Fc region of an immunoglobulin (e.g., an Fc region described herein) linked (e.g., fused) to a protein or peptide. The Fc region may be directly linked (e.g., genetically fused) to the protein or peptide, for example, via a linker. In one embodiment, the Fc region is derived from the Fc region of an IgG, e.g., human IgG, e.g., IgG1, IgG2, IgG3, or IgG4. In one embodiment, the Fc region is derived from the Fc region of an IgG1, e.g., human IgG1.

[0414] An IL-2 fusion protein can comprise an IL-2 variant (e.g., an IL-2 variant described herein) or a functional fragment thereof linked (e.g., fused) to a protein or peptide. In one embodiment, the IL-2 fusion protein is an IL-2-Fc fusion protein, e.g., further comprising an Fc region of an immunoglobulin (e.g., an Fc region described herein) linked (e.g., fused) to an IL-2 polypeptide (e.g., an IL-2 variant described herein) or a functional fragment thereof. In one embodiment, the IL-2 fusion protein is not an IL-2-Fc fusion protein, e.g., an IL-2 fusion variant described herein, or a functional fragment thereof, but is linked (e.g., fused) to a protein or peptide other than the Fc region of an IgG, e.g., human IgG, e.g., IgG1, IgG2, IgG3, or IgG4.

[0415] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO: SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0416] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID 2. An amino acid sequence selected from SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, or SEQ ID NO:131, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.

[0417] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:1 SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, or SEQ ID NO:169, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0418] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:2 SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, or SEQ ID NO:207, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0419] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:2 SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, or SEQ ID NO:245, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0420] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:283, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:3 SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, or SEQ ID NO:283, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0421] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:3 SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, or SEQ ID NO:321, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0422] In one embodiment, the IL-2 fusion protein is selected from the group consisting of SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO: SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, or SEQ ID NO:359, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0423] In one embodiment, the IL-2 fusion protein comprises an amino acid sequence selected from: 1004, SEQ ID NO:1005, SEQ ID NO:1006, SEQ ID NO:1007, SEQ ID NO:1008, SEQ ID NO:1009, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or which differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1004, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1005, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1006, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1007, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto. In one embodiment, the IL-2 fusion protein comprises the amino acid sequence of SEQ ID NO: 1008, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0424] In one embodiment, the IL-2 agent comprises the amino acid sequence of any of SEQ ID NOs: 1004-1009, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1007 or 1008, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1004, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1005, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1006, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1007, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1008, or a functional fragment thereof. In one embodiment, the IL-2 agent comprises the amino acid sequence of SEQ ID NO: 1009, or a functional fragment thereof.

[0425] Without wishing to be bound by theory, it is also believed that in one embodiment, an IL-2 fusion protein comprising the amino acid sequence of SEQ ID NO: 1008, or a functional fragment thereof, may have at least one or more of the following advantageous properties: (i) a reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) relative to other T cell types; (ii) significantly stable, e.g., due to the presence of stabilizing V69A and Q74P mutations; (iii) a reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) relative to other T cell types; (iv) a reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) relative to other T cell types; (v) a reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) relative to other T cell types; (vi) a reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) relative to other T cell types; (vii) a reduced binding affinity for CD122 and / or CD132, increasing the potency and selectivity of IL-2 agents for regulatory T cells (Tregs) relative to other T cell types; (viii ... (iv) have reduced or decreased binding ability and / or affinity for CD25, improving the longevity of the IL-2 agent; (iv) do not substantially promote the expansion, activation, survival, and / or proliferation of T effector cells and / or natural killer (NK) cells in vitro and / or in vivo; (v) have reduced misdisulfide pairing and improved stability, e.g., due to the presence of the C125S mutation; and / or (vi) have reduced effector function due, e.g., to reduced Fc glycosylation, e.g., due to the N297G mutation in the Fc region. In one embodiment, an IL-2 agent comprising the H16L mutation has reduced binding affinity for CD122 and / or CD132 and / or increased potency and selectivity for Tregs over other T cell types, compared to IL-2 agents comprising other H16 mutations. These properties make an IL-2 fusion protein comprising the amino acid sequence of SEQ ID NO: 1008 particularly suitable for the treatment of disorders and conditions resulting from an aberrant immune response, such as autoimmune diseases.

[0426] Thus, in one embodiment, an IL-2 fusion protein comprising the amino acid sequence SEQ ID NO: 1008, or a functional fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or differing by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 45, or 50 or fewer amino acids thereto, possesses, inter alia, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, or all) of the following properties compared to wild-type IL-2 or a reference IL-2 fusion protein that does not contain the amino acid substitutions: (i) Ability to differentiate in vitro or in vivo; (ii) reduced or decreased binding capacity and / or binding affinity to human CD122 in vitro and / or in vivo; (iii) reduced or decreased binding capacity and / or binding affinity to human CD132 in vitro and / or in vivo; (iv) reduced or decreased affinity of the IL-2 fusion protein for the heterodimeric IL-2 receptor composed of human CD122 and human CD132 (i.e., human CD122 / CD132 heterodimer) in vitro and / or in vivo; (v) reduced or decreased, or substantially unchanged, binding capacity and / or binding affinity to human CD25 in vitro and / or in vivo; (vi) reduced or decreased, or substantially unchanged, binding capacity and / or binding affinity to regulatory T cells (e.g., Foxp3 + (vii) selective activation of the IL-2 signaling pathway in regulatory T cells (Tregs) in vitro or in vivo; (viii) enhanced or increased ability to induce or promote the expansion, activity, survival and / or proliferation of Tregs; or (ix) reduced or decreased effector function.

[0427] In one embodiment, the IL-2 fusion protein comprises, from N- to C-terminus, an IL-2 variant described herein and an Fc region (e.g., an Fc region described herein). In one embodiment, the fusion protein further comprises a linker (e.g., a linker described herein) between the IL-2 variant and the Fc region. In one embodiment, the IL-2 fusion forms a dimer, e.g., a homodimer.

[0428] In one embodiment, the fusion protein comprises one or more glycosylation sites or is glycosylated, hi another embodiment, the fusion protein does not have a glycosylation site or is unglycosylated.

[0429] In one embodiment, the only amino acids in the fusion protein are canonical amino acids. In one embodiment, the fusion protein includes naturally occurring amino acids; their analogs, derivatives, and congeners; amino acid analogs with variant side chains; and / or all stereoisomers of any of the foregoing. The fusion protein may include D- or L-optical isomers of amino acids and peptidomimetics.

[0430] In one aspect, the present disclosure provides a method for producing the IL-2 fusion proteins disclosed herein. The IL-2 fusion proteins described herein can be produced by any suitable recombinant DNA technology. In one embodiment, the method comprises culturing cells containing a nucleic acid encoding the IL-2 fusion protein under conditions that allow for production of the fusion protein. In another embodiment, the method further comprises isolating or purifying the IL-2 fusion protein. In yet another embodiment, the method further comprises evaluating the efficacy of the IL-2 fusion protein in a cell-based assay or animal model. In yet another embodiment, the method further comprises administering the IL-2 fusion protein to a subject, e.g., a human.

[0431] The present disclosure provides isolated nucleic acid molecules encoding the IL-2 fusion proteins described herein, as well as vectors and host cells thereof. Nucleic acid molecules include, but are not limited to, RNA, genomic DNA, and cDNA.

[0432] IL-2 complex In one embodiment, the IL-2 agent comprises an IL-2 complex, such as an IL-2 complex described herein. In one embodiment, the IL-2 complex is an IL-2 / anti-IL-2 antibody immune complex (IL-2ic).

[0433] Without wishing to be bound by theory, in one embodiment, IL-2 complexes, such as IL-2 / anti-IL-2 antibody immune complexes, are believed to enhance the biological activity of IL-2 in vivo. For example, the effects of IL-2 on cells (e.g., Tregs) can be modulated by conjugating IL-2 with a different mAb that specifically binds to IL-2. This mechanism may include, for example, extending the cytokine's half-life in circulation. Depending on the clone of the IL-2 antibody, IL-2ic can selectively stimulate, for example, CD25high cells (e.g., IL-2 / JES6-1 immune complexes) or CD122high cells (e.g., IL-2 / S4B6 immune complexes). For example, IL-2 / JES6-1 immune complexes highly selectively stimulate regulatory T cells, which may be useful in the treatment of transplantation and autoimmune diseases. As another example, IL-2 / S4B6 immune complexes have high stimulatory activity for NK cells and can memory CD8+ T cells, potentially replacing conventional IL-2 in cancer immunotherapy.

[0434] In one embodiment, the IL-2 complex comprises an IL-2 variant described herein. In one embodiment, the IL-2 complex comprises one or more amino acid changes (e.g., substitutions) set forth in Table 9. In one embodiment, the IL-2 complex comprises an amino acid sequence set forth in Table 9, or a functional fragment thereof. In one embodiment, the IL-2 complex comprises an anti-IL-2 antibody molecule. In one embodiment, the IL-2 complex comprises an IL-2 variant and an anti-IL-2 antibody molecule described herein. In one embodiment, the anti-IL-2 antibody molecule binds to the IL-2 variant. In one embodiment, the anti-IL-2 antibody molecule is capable of binding to the IL-2 variant and wild-type IL-2. In one embodiment, the IL-2 variant comprises one or more mutations described herein. In one embodiment, the one or more mutations do not reduce or do not substantially reduce binding of the IL-2 variant to the anti-IL-2 antibody molecule.

[0435] In one embodiment, the IL-2 complex is SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 3, an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing therefrom by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids.

[0436] In one embodiment, the IL-2 complex modulates (e.g., stimulates) one or more activities of T cells. In one embodiment, the IL-2 complex stimulates CD25high cells. In one embodiment, the IL-2 complex stimulates Tregs. In one embodiment, the IL-2 complex stimulates CD122high cells. In one embodiment, the IL-2 complex stimulates NK cells and / or memory CD8+ T cells. In one embodiment, the IL-2 complex selectively stimulates CD25high cells over CD122high cells. In one embodiment, the IL-2 complex selectively stimulates CD122high cells over CD25high cells. In one embodiment, the IL-2 complex selectively stimulates Tregs over NK cells and / or memory CD8+ T cells. In one embodiment, the IL-2 complex selectively stimulates NK cells and / or memory CD8+ T cells over Tregs.

[0437] Exemplary anti-IL-2 antibody molecules suitable for use are described, for example, in International Application Publication No. WO 2016 / 164937, which is incorporated herein by reference in its entirety.

[0438] As used herein, the term "antibody molecule" refers to a protein, such as an immunoglobulin chain, or a fragment thereof containing at least one immunoglobulin variable domain sequence. The term "antibody molecule" includes, for example, full-length mature antibodies and antigen-binding fragments of antibodies. For example, an antibody molecule can contain a heavy (H) chain variable domain sequence (abbreviated herein as VH) and a light (L) chain variable domain sequence (abbreviated herein as VL). In another example, an antibody molecule contains two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequences, thereby forming two antigen-binding sites, such as Fab, Fab', F(ab'), Fc, Fd, Fd', Fv, single-chain antibodies (e.g., scFv), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies (which can be produced by modification of whole antibodies or those synthesized de novo using recombinant DNA technology). These functional antibody fragments retain the ability to selectively bind to their respective antigens or receptors. Antibodies and antibody fragments can be derived from any class of antibody, including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and any subclass (e.g., IgG1, IgG2, IgG3, and IgG4). Antibody molecules can be monoclonal or polyclonal. Antibody molecules can also be human, humanized, CDR-grafted, or in vitro-generated. Antibody molecules can have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. Antibody molecules can also have a light chain selected from, for example, a kappa light chain or a lambda light chain. The term "immunoglobulin" (Ig) is used interchangeably with the term "antibody" herein.

[0439] Examples of antigen-binding fragments include: (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; (ii) an F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a diabody (dAb) fragment consisting of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single-chain Fv (scFv) (see, e.g., Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883); and (viii) a single-domain antibody. These antibody fragments can be obtained using any suitable method, including several conventional techniques known to those with skill in the art, and the fragments can be screened for utility in the same manner as are intact antibodies.

[0440] The term "antibody" includes intact molecules and functional fragments thereof. The constant region of an antibody can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function).

[0441] The antibody molecule can be a single-chain antibody. Single-chain antibodies (scFV) can be engineered (see, for example, Colcher D. et al. (1999) Ann NY Acad Sci 880:263-80; and Reiter Y. (1996) Clin Cancer Res 2:245-52). Single-chain antibodies can be dimerized or multimerized to generate multivalent antibodies with specificity for different epitopes of the same target protein.

[0442] The antibody molecules disclosed herein may also be single-domain antibodies. Single-domain antibodies may include antibodies whose complementarity-determining regions are portions of a single-domain polypeptide. Examples include, but are not limited to, heavy-chain antibodies, which are antibodies that naturally lack light chains, single-domain antibodies derived from conventional four-chain antibodies, engineered antibodies, and single-domain scaffolds other than those derived from antibodies. Single-domain antibodies may be any of those in the art or any future single-domain antibodies. Single-domain antibodies may be derived from any species, including, but not limited to, mouse, human, camel, llama, fish, shark, goat, rabbit, and cow. According to some embodiments, the single-domain antibody is a naturally occurring single-domain antibody known as a heavy-chain antibody lacking light chains. Such single-domain antibodies are disclosed, for example, in WO 94 / 04678. For clarity, this variable domain derived from a heavy-chain antibody that naturally lacks light chains is known herein as a VHH or nanobody to distinguish it from the conventional VH of four-chain immunoglobulins. Such VHH molecules can be derived from antibodies raised in Camelidae species, such as camels, llamas, dromedaries, alpacas, and guanacos. Other species outside of Camelidae can produce heavy chain antibodies that naturally lack light chains; such VHHs are also contemplated.

[0443] The VH and VL regions can be subdivided into regions of hypervariability termed "complementarity-determining regions" (CDRs) interspersed with more conserved regions termed "framework regions" (FR or FW). As used herein, the terms "complementarity-determining region" and "CDR" refer to amino acid sequences within an antibody variable region that confer antigen specificity and binding affinity. As used herein, the terms "framework," "FW," and "FR" are used interchangeably.

[0444] The extent of framework regions and CDRs has been precisely defined in a number of ways (see Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242; Chothia, C et al., (1987) J. Mol. Biol. 196:901-917; and the AbM definition used by Oxford Molecular's AbM antibody modeling software). See generally, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). In one embodiment, the following definitions are used: the AbM definition for CDR1 of the heavy chain variable domain and the Kabat definitions for the other CDRs. In one embodiment, the Kabat definitions are used for all CDRs. In addition, embodiments described in Kabat or with respect to AbM CDRs can also be implemented using Chothia hypervariable loops. Each VH and each VL typically comprises three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0445] As used herein, "immunoglobulin variable domain sequence" refers to an amino acid sequence that can form the structure of an immunoglobulin variable domain. For example, the sequence can include all or part of the amino acid sequence of a naturally occurring variable domain. For example, the sequence can include or not include one, two, or more N- or C-terminal amino acids, or can include other changes compatible with the formation of a protein structure.

[0446] The term "antigen-binding region" refers to the portion of an antibody molecule that contains determinants that form the interface that binds to an antigen or its epitope. In the context of a protein (or protein mimetic), the antigen-binding region typically includes one or more loops (e.g., of at least four amino acids or amino acid mimetics) that form the interface that binds to the antigen. Typically, the antigen-binding region of an antibody molecule includes at least one or two CDRs and / or hypervariable loops, or more typically at least three, four, five, or six CDRs and / or hypervariable loops.

[0447] The terms "compete" or "cross-compete" are used interchangeably herein to refer to the ability of an antibody molecule to interfere with the binding of another antibody molecule to a target. Interference with binding can be direct or indirect (e.g., via allosteric modulation of the antibody molecule or the target). The extent to which an antibody molecule can interfere with the binding of another antibody molecule to a target, and therefore can be said to compete, can be determined using a competitive binding assay, such as a FACS assay, ELISA, or BIACORE assay. In one embodiment, the competitive binding assay is a quantitative competitive assay. In one embodiment, a first antibody molecule is said to compete with a second antibody molecule for binding to a target if binding of the first antibody molecule to the target is reduced by 10% or more, e.g., 20% or more, 30% or more, 40% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more in a competitive binding assay (e.g., a competitive assay described herein).

[0448] As used herein, the terms "monoclonal antibody" or "monoclonal antibody composition" refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Monoclonal antibodies may be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).

[0449] A "virtually human" protein is one that does not elicit a neutralizing antibody response, such as a human anti-mouse antibody (HAMA) response. HAMA can be a problem in many situations, for example, when antibody molecules are repeatedly administered in the treatment of chronic or recurrent disease states. Due to increased clearance of antibodies from serum (see, e.g., Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)), and even due to potential allergic reactions (see, e.g., LoBuglio et al., Hybridoma, 5:5117-5123 (1986)), HAMA responses can potentially render repeated antibody administration ineffective.

[0450] The antibody molecule may be a polyclonal or monoclonal antibody. In one embodiment, the antibody may be recombinantly produced (e.g., produced by any suitable phage display or combinatorial method).

[0451] Various phage display and combinatorial methods for generating antibodies are known in the art (e.g., Ladner et al., U.S. Pat. No. 5,223,409; Kang et al., WO 92 / 18619; Dower et al., WO 91 / 17271; Winter et al., WO 92 / 20791; Markland et al., WO 92 / 15679; Breitling et al., WO 93 / 01288; McCafferty et al., WO 92 / 01047; Garrard et al., WO 92 / 09690; Ladner et al., WO 90 / 02809; Fuchs et al., (1991) Bio / Technology 9:1370-1372; Hay et al., (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio / Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982 (the contents of all of which are incorporated herein by reference).

[0452] In one embodiment, the antibody molecule is a fully human antibody (e.g., an antibody made in a mouse genetically engineered to produce antibodies derived from human immunoglobulin sequences) or a non-human antibody, such as a rodent (mouse or rat) antibody, a goat antibody, a primate (e.g., monkey) antibody, or a camel antibody. In one embodiment, the non-human antibody is rodent (mouse or rat antibody). Methods for producing rodent antibodies are known in the art.

[0453] Human monoclonal antibodies can be generated using transgenic mice carrying human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with an antigen of interest are used to produce hybridomas secreting human mAbs with specific affinity for epitopes derived from human proteins (e.g., Wood et al., WO 91 / 00906; Kucherlapati et al., WO 91 / 10741; Lonberg et al., WO 92 / 03918; Kay et al., WO 92 / 03917; Lonberg et al., 1994 Nature 368:856-859; Green, LL et al., 1994 Nature Genet. 7:13-21; Morrison, SL et al., 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al., 1993 Year Immunol 7:33-40; Tuaillon et al., 1993 PNAS 90:3720-3724; Bruggeman et al., 1991 Eur J Immunol 21:1323-1326).

[0454] The antibody may have a variable region or a portion thereof, such as a CDR, generated in a non-human organism, such as a rat or a mouse. Chimeric antibodies, CDR-grafted antibodies, and humanized antibodies are within the scope of the present invention. Antibodies generated in a non-human organism, such as a rat or a mouse, and then modified, for example, in the variable framework or constant region to reduce antigenicity in humans are also within the scope of the present invention.

[0455] Chimeric antibodies can be produced by any suitable recombinant DNA technique. Some are known in the art (Robinson et al., International Publication No. PCT / US86 / 02269; Akira et al., European Patent Application No. 184,187; Taniguchi, M., European Patent Application No. 171,496; Morrison et al., European Patent Application No. 173,494; Neuberger et al., International Application No. 86 / 01533; Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent Application No. 125,023; Better et al., (1988 Science 240:1041-1043); Liu et al., (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al., (1987) PNAS 84:214-218; Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al., (1985) Nature 314:446-449; and Shaw et al., 1988, J. Natl. Cancer Inst. 80:1553-1559).

[0456] A humanized or CDR-grafted antibody will have at least one or two, but generally all three, recipient CDRs (of the immunoglobulin heavy and / or light chain) replaced with donor CDRs. The antibody may have at least a portion of non-human CDRs replaced, or only a portion of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs necessary for binding of the humanized antibody to lipopolysaccharide. In one embodiment, the donor will be a rodent antibody, such as a rat or mouse antibody, and the recipient will be a human framework or human consensus framework. Typically, the immunoglobulin providing the CDRs is referred to as the "donor," and the immunoglobulin providing the framework is referred to as the "acceptor." In one embodiment, the donor immunoglobulin is non-human (e.g., rodent). The acceptor framework is typically a naturally occurring (e.g., human) framework or consensus framework, or a sequence about 85% or more identical thereto, e.g., 90%, 95%, 99% or more identical thereto.

[0457] As used herein, the term "consensus sequence" refers to a sequence formed from the amino acids (or nucleotides) that occur most frequently in a family of related sequences (see, e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of proteins, each position in the consensus sequence is occupied by the amino acid that occurs most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. "Consensus framework" refers to the framework region in a consensus immunoglobulin sequence.

[0458] Antibodies may be humanized by any suitable method, several such methods being known in the art (see, e.g., Morrison, SL, 1985, Science 229:1202-1207, by Oi et al., 1986, BioTechniques 4:214, and U.S. Patent Nos. 5,585,089, 5,693,761, and 5,693,762 by Queen et al., the contents of all of which are incorporated herein by reference).

[0459] Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR-substitution, which can replace one, two, or all of the CDRs of an immunoglobulin chain. See, e.g., U.S. Pat. No. 5,225,539; Jones et al., 1986 Nature 321:552-525; Verhoeyan et al., 1988 Science 239:1534; Beidler et al., 1988 J. Immunol. 141:4053-4060; Winter, U.S. Pat. No. 5,225,539 (the contents of all of which are expressly incorporated herein by reference). Winter describes a CDR-grafting method that can be used to prepare humanized antibodies (GB Patent Application Publication No. 2188638, filed March 26, 1987; Winter, U.S. Pat. No. 5,225,539 (the contents of which are expressly incorporated herein by reference)).

[0460] Humanized antibodies in which specific amino acids have been substituted, deleted, or added are also provided. Criteria for selecting donor-derived amino acids are described, for example, in U.S. Patent No. 5,585,089, e.g., columns 12-16 of U.S. Patent No. 5,585,089, the contents of which are incorporated herein by reference. Other techniques for humanizing antibodies are described in Padlan et al., EP 519596, published December 23, 1992.

[0461] In one embodiment, the antibody molecule has a heavy chain constant region selected from, for example, the heavy chain constant regions of IgG1, IgG2 (e.g., IgG2a), IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly, for example, the (e.g., human) heavy chain constant regions of IgG1, IgG2, IgG3, and IgG4. In another embodiment, the antibody molecule has a light chain constant region selected from, for example, the (e.g., human) light chain constant regions of kappa or lambda. The constant region can be altered, e.g., mutated, to modify the properties of the antibody molecule (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, and / or complement function). In one embodiment, the antibody molecule has effector function and can bind complement. In another embodiment, the antibody molecule does not recruit effector cells or bind complement. In a specific embodiment, the antibody molecule has reduced or no Fc receptor binding ability. For example, it can be an isotype or subtype, fragment or other variant that does not support binding to an Fc receptor, eg, it has a mutagenized or deleted Fc receptor binding region.

[0462] In one embodiment, the constant region of the antibody molecule is altered. Methods for altering antibody constant regions are known in the art. Antibody molecules with altered function, such as altered affinity for effector ligands, such as cellular FcR or the C1 component of complement, can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see, for example, European Patent Application Publication No. 388,151, U.S. Patent No. 5,624,821, and U.S. Patent No. 5,648,260, the entire contents of which are incorporated herein by reference). Amino acid mutations that stabilize antibody structure in human IgG4, such as S228P (EU nomenclature, S241P in Kabat nomenclature), are also contemplated. Similar types of changes that would reduce or eliminate these functions when applied to immunoglobulins of murine or other species can be described.

[0463] In some embodiments, the only amino acids in an antibody molecule are canonical amino acids. In some embodiments, an antibody molecule includes naturally occurring amino acids; their analogs, derivatives, and congeners; amino acid analogs with modified side chains; and / or all stereoisomers of any of the foregoing. An antibody molecule may include D or L optical isomers of amino acids and peptidomimetics.

[0464] The polypeptides of the antibody molecules described herein may be linear or branched, may contain modified amino acids, or may be interrupted by non-amino acids. Antibody molecules may also be modified by any other manipulation, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or conjugation with a labeling component. Polypeptides may be isolated from natural sources, produced by recombinant methods in eukaryotic or prokaryotic hosts, or may be the product of synthetic procedures.

[0465] The antibody molecules described herein can be used alone in unconjugated form or can be conjugated to a substance, e.g., a toxin or moiety (e.g., a therapeutic agent; a compound that emits radiation; a molecule of plant, fungal, or bacterial origin; or a biological protein (e.g., a protein toxin) or biological particle (e.g., a recombinant viral particle, e.g., via a viral coat protein). For example, the antibody molecule can be coupled to a radioisotope, such as an alpha-emitter, a beta-emitter, or a gamma-emitter, or a beta and gamma-emitter.

[0466] Antibody molecules can also be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a "derivatized" antibody molecule is a modified antibody molecule. Derivatization methods include, but are not limited to, the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme, or an affinity ligand such as biotin. Thus, antibody molecules are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules. For example, antibody molecules can be functionally linked (by chemical coupling, genetic fusion, noncovalent association, or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or diabody), a detectable agent, a toxin, a drug, and / or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (e.g., a streptavidin core region or a polyhistidine tag).

[0467] Some types of derivatized antibody molecules are produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies). Suitable crosslinkers include heterobifunctional crosslinkers, which have two distinctly different reactive groups separated by a suitable spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester), or homobifunctional crosslinkers (e.g., disuccinimidyl suberate). Such linkers are commercially available from Pierce Chemical Company, Rockford, Ill.

[0468] Useful detectable agents with which anti-dengue antibody molecules may be derivatized (or labeled) include fluorescent compounds, various enzymes, prosthetic groups, luminescent materials, bioluminescent materials, fluorescence-emitting metal atoms such as europium (Eu) and other lanthanides, and radioactive materials (described below). Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-naphthalenesulfonyl chloride, phycoerythrin, and the like. Antibodies can also be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, β-galactosidase, acetylcholinesterase, glucose oxidase, and the like. When an antibody is derivatized with a detectable enzyme, the detectable enzyme can be detected by adding additional reagents that the enzyme uses to produce a detectable reaction product. For example, in the presence of the detectable agent horseradish peroxidase, the addition of hydrogen peroxide and diaminobenzidine results in a detectable, colored reaction product. Antibody molecules can also be derivatized with prosthetic groups (e.g., streptavidin / biotin and avidin / biotin). For example, antibodies can be derivatized with biotin and detected through indirect measurement of avidin or streptavidin binding. Examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, or phycoerythrin; an example of a luminescent material includes luminol, and examples of bioluminescent materials include luciferase, luciferin, and aequorin.

[0469] Labeled antibody molecules can be used, for example, diagnostically and / or experimentally, in a number of contexts, including: (i) isolating a given antigen by standard methods such as affinity chromatography or immunoprecipitation; (ii) detecting a given antigen (e.g., in a cell lysate or cell supernatant) to assess protein abundance and expression patterns; and (iii) monitoring protein levels in tissues, for example, as part of a clinical trial procedure to determine the effectiveness of a given treatment regimen.

[0470] An antibody molecule can be conjugated to another molecular entity, typically a labeling agent or moiety or a therapeutic agent or moiety (e.g., an antimicrobial agent or moiety (e.g., an antibacterial agent or moiety, or a bactericidal agent or moiety), an immunomodulatory agent or moiety, an immunostimulatory agent or moiety, a cytotoxic agent or moiety, or a cytostatic agent or moiety). Radioisotopes can be used in diagnostic and therapeutic applications. Radioisotopes that can be coupled to antibody molecules include, but are not limited to, alpha-emitters, beta-emitters, or gamma-emitters, or beta and gamma-emitters. Such radioisotopes include iodine ( 131 I or 125 I), yttrium ( 90 Y), lutetium ( 177 Lu), actinium ( 225 Ac), praseodymium, astatine ( 211 At), rhenium ( 186 Re), Bismuth ( 212 Bi or 213 Bi), Indium ( 111 In), technetium ( 99m Tc), phosphorus ( 32 P), rhodium ( 188 Rh), sulfur ( 35 S), carbon ( 14 C), tritium ( 3 H), chromium ( 51 Cr), chlorine ( 36 Cl), cobalt ( 57Co or 58 Co), iron ( 59 Fe), Selenium ( 75 Se), or gallium ( 67 Radioisotopes useful as therapeutic agents include, but are not limited to, yttrium ( 90 Y), lutetium ( 177 Lu), actinium ( 225 Ac), praseodymium, astatine ( 211 At), rhenium ( 186 Re), Bismuth ( 212 Bi or 213 Bi), and rhodium ( 188 For example, radioisotopes useful as labels for use in diagnostic methods include iodine ( 131 I or 125 I), indium ( 111 In), technetium ( 99m Tc), phosphorus ( 32 P), carbon ( 14 C), and tritium ( 3 H), or one or more of the therapeutic isotopes listed above.

[0471] In one aspect, the present disclosure provides a method of producing an IL-2 complex described herein. The method includes, for example, contacting an IL-2 variant described herein with an anti-IL-2 antibody molecule (e.g., an anti-IL-2 antibody molecule that binds to the IL-2 variant), thereby producing an IL-2 complex. In one embodiment, the method further includes evaluating the efficacy of the IL-2 complex in vitro, ex vivo, or in vivo.

[0472] The present disclosure provides isolated nucleic acid molecules encoding the IL-2 complexes (or portions thereof) described herein, as well as vectors and host cells thereof. Nucleic acid molecules include, but are not limited to, RNA, genomic DNA, and cDNA.

[0473] IL-2 conjugates In one embodiment, the IL-2 agent comprises a conjugate, eg, an IL-2 conjugate described herein.

[0474] In one embodiment, the IL-2 conjugate comprises an IL-2 variant described herein and a non-IL-2 moiety. In one embodiment, the IL-2 conjugate comprises one or more amino acid changes (e.g., substitutions) set forth in Table 9. In one embodiment, the IL-2 conjugate comprises an amino acid sequence set forth in Table 9, or a functional fragment thereof. In one embodiment, the non-IL-2 moiety comprises an antibody molecule, e.g., an antibody molecule described herein. In one embodiment, the non-IL-2 moiety comprises a polymer, e.g., a polyether compound. In one embodiment, the polyether compound comprises polyethylene glycol (PEG). In one embodiment, the non-IL-2 moiety comprises a cytokine. The IL-2 variant can be attached to the non-IL-2 moiety directly or indirectly, e.g., via a linker. In one embodiment, the IL-2 conjugate is an IL-2 fusion protein.

[0475] In one embodiment, the IL-2 conjugate is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:1000, SEQ ID NO:1001, SEQ ID NO:1002, or an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 amino acids thereto.

[0476] In one embodiment, the IL-2 conjugate is an immunoconjugate, for example, comprising an antibody molecule. In one embodiment, the IL-2 variant is bound to the antibody molecule by a covalent bond. In one embodiment, the IL-2 variant is bound to the antibody molecule by a peptide bond. In one embodiment, the IL-2 variant and the antibody molecule form a fusion protein. In one embodiment, the fusion protein comprises a linker between the IL-2 variant and the antibody molecule (e.g., the heavy chain, the light chain, or both). In one embodiment, the IL-2 variant is bound to the antibody molecule by a non-peptide bond. In one embodiment, the IL-2 variant is not bound to the antibody molecule by a non-peptide bond.

[0477] In one embodiment, the IL-2 variant is attached to the backbone of the antibody molecule. In another embodiment, the IL-2 variant is attached to a side chain of the antibody molecule. In one embodiment, the antibody molecule is attached to the backbone of the IL-2 variant. In one embodiment, the antibody molecule is attached to the side chain of the IL-2 variant.

[0478] In one embodiment, two or more (e.g., three, four, five, six, seven, eight, or more) IL-2 variants are attached to the antibody molecule. In one embodiment, four IL-2 variants are attached to the antibody molecule. For example, the IL-2 variants may be the same, or at least some of the IL-2 variants may be diffe...

Claims

1. 1. An IL-2 agent for use in a method of treating or preventing skin graft rejection in a subject, comprising: the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, the IL-2 variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1; (i) the amino acid substitutions H16L, H16N, or I92S, and (ii) the amino acid substitutions V69A, and Q74P IL-2 agonist comprising:

2. 2. The method of claim 1, wherein the subject has undergone, is undergoing, or is planning to undergo a skin graft.

3. The IL-2 agent for use according to any one of claims 1 to 2, wherein the skin graft rejection is graft-versus-host disease (GVHD).

4. An IL-2 agonist for use in a method of pretreating a subject prior to skin grafting, comprising: the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, the IL-2 variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1; (i) the amino acid substitutions H16L, H16N, or I92S, and (ii) amino acid substitutions V69A, Q74P IL-2 agonist comprising:

5. Pretreating the subject prior to said skin grafting, (i) increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample); (ii) increasing the ratio of regulatory T cells to non-regulatory T cells in said subject or in a sample from said subject (e.g., a peripheral blood sample), optionally wherein said ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 fold or more; or (iii) increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), optionally wherein the ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 fold or more; 5. The IL-2 agent for use according to claim 4, comprising:

6. 6. The IL-2 agent for use according to any one of claims 4 to 5, wherein the method further comprises administering the IL-2 agent during and / or after the skin grafting.

7. 1. An IL-2 agent for use in a method of inducing and / or modulating (e.g., increasing) immunosuppression or selectively increasing regulatory T cells in a subject, comprising: the subject has had, is having, or will have a skin graft; the IL-2 agent is an IL-2 variant or an IL-2 fusion protein comprising the IL-2 variant, the IL-2 variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1; (i) the amino acid substitutions H16L, H16N, or I92S, and (ii) the amino acid substitutions V69A, and Q74P IL-2 agonist comprising:

8. Increasing immunosuppression in a subject (i) increasing the number of regulatory T cells in the subject or in a sample from the subject (e.g., a peripheral blood sample); (ii) increasing the ratio of regulatory T cells to non-regulatory T cells in said subject or in a sample from said subject (e.g., a peripheral blood sample), optionally wherein said ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 fold or more; (iii) increasing the ratio of regulatory T cells to NK cells in the subject or in a sample from the subject (e.g., a peripheral blood sample), optionally wherein the ratio is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 fold or more; Contains, or The regulatory T cell is (i) about a 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or about a 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more increase compared to non-regulatory T cells; (ii) about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or about 2, 3, 4, 5, 6, 7, 8, 9, 10 fold or more increased compared to NK cells; (iii) is increased by about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or by about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more fold compared to non-regulatory CD4+ T cells; or (iv) about a 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more, or about a 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more increase compared to CD8+ cells; 8. An IL-2 agent for use according to claim 7.

9. An IL-2 agent for use as described in any one of claims 1 to 8 as a medicament in combination with a skin transplant.

10. 10. An IL-2 agent for use according to claim 9 in preventing skin graft rejection in a subject.

11. The IL-2 agent for use according to claim 10, wherein the skin graft rejection is graft-versus-host disease (GVHD).

12. 10. An IL-2 agent for use according to claim 9 in inducing and / or modulating (e.g. increasing) immunosuppression in a subject or in selectively increasing regulatory T cells in a subject.

13. The IL-2 agent for use according to any one of claims 10 to 12, wherein the IL-2 agent is administered to the subject before, during and / or after the skin grafting.

14. 14. The IL-2 agent for use according to any one of claims 1 to 13, further comprising administration of one or more additional immunosuppressants selected from cyclosporine, tacrolimus, mycophenolate mofetil, prednisone, azathioprine, sirolimus, daclizumab, or basiliximab.

15. The IL-2 agent for use according to any one of claims 1 to 14, wherein the IL-2 agent is an IL-2 variant.

16. 15. The IL-2 agent for use according to any one of claims 1 to 14, wherein the IL-2 agent is an IL-2 fusion protein.

17. 17. The IL-2 agent for use according to any one of claims 1 to 16, wherein said IL-2 variant further comprises the amino acid substitution T3A.

18. The IL-2 variant is (i) the amino acid sequence of any one of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002; or (ii) an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002; 18. An IL-2 agent for use according to any one of claims 1 to 17, comprising:

19. An IL-2 active substance for use according to any one of claims 1 to 18, wherein the IL-2 variant comprises the amino acid sequence of sequence no.

5.

20. 20. The IL-2 agent for use according to any one of claims 1 to 14 or 16 to 19, wherein the IL-2 fusion protein further comprises an Fc region, optionally wherein the Fc region comprises an Fc region of IgG1 allotype m3 comprising an N297G substitution according to EU numbering.

21. The Fc region is (i) the amino acid sequence of SEQ ID NO: 1003, or (ii) an IL-2 agent for use according to claim 20, comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 1003.

22. 22. The IL-2 agent for use according to any one of claims 20 to 21, wherein the Fc region is fused to the C-terminus of the IL-2 variant.

23. 23. The IL-2 agent for use according to any one of claims 1 to 14 or 16 to 22, wherein the IL-2 fusion protein further comprises a linker, optionally wherein the linker comprises (G 4 S) 4 (SEQ ID NO:48).

24. The fusion protein is (i) the amino acid sequence of any one of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008, or 1009; or (ii) An IL-2 agent for use according to any one of claims 1 to 14 or 16 to 23, comprising an amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 1004, 1005, 1006, 1007, 1008 or 1009.

25. An IL-2 agent for use according to any one of claims 1 to 14 or 16 to 24, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 1008.

26. 26. The IL-2 agent for use according to any one of claims 1 to 14 or 16 to 25, wherein the fusion protein forms a dimer.